##### Table of Contents

Q3 false--12-31 0001000697 0001000697 2025-01-01 2025-09-27 0001000697 2025-06-29 2025-09-27 0001000697 2024-06-30 2024-09-28 0001000697 2024-01-01 2024-09-28 0001000697 2025-09-27 0001000697 2024-12-31 0001000697 2025-05-22 2025-05-22 0001000697 2024-09-28 0001000697 2025-10-31 0001000697 2023-12-31 0001000697 2024-06-29 0001000697 2025-06-28 0001000697 us-gaap:ServiceMember 2024-06-30 2024-09-28 0001000697 us-gaap:ProductMember 2024-06-30 2024-09-28 0001000697 wat:TaServiceMember 2024-06-30 2024-09-28 0001000697 wat:WatersServiceMember 2024-06-30 2024-09-28 0001000697 wat:ChemistryConsumablesMember 2024-06-30 2024-09-28 0001000697 wat:WatersInstrumentSystemsMember 2024-06-30 2024-09-28 0001000697 wat:TaInstrumentSystemsMember 2024-06-30 2024-09-28 0001000697 wat:AsiaOtherMember 2024-06-30 2024-09-28 0001000697 country:CN 2024-06-30 2024-09-28 0001000697 wat:AmericasOtherMember 2024-06-30 2024-09-28 0001000697 country:US 2024-06-30 2024-09-28 0001000697 srt:AsiaPacificMember 2024-06-30 2024-09-28 0001000697 srt:EuropeMember 2024-06-30 2024-09-28 0001000697 srt:AmericasMember 2024-06-30 2024-09-28 0001000697 wat:GovernmentalAndAcademicCustomersMember 2024-06-30 2024-09-28 0001000697 wat:PharmaceuticalCustomersMember 2024-06-30 2024-09-28 0001000697 wat:IndustrialCustomersMember 2024-06-30 2024-09-28 0001000697 wat:ChemistryConsumablesMember us-gaap:TransferredAtPointInTimeMember 2024-06-30 2024-09-28 0001000697 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2024-06-30 2024-09-28 0001000697 us-gaap:TransferredAtPointInTimeMember 2024-06-30 2024-09-28 0001000697 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2024-06-30 2024-09-28 0001000697 us-gaap:TransferredOverTimeMember 2024-06-30 2024-09-28 0001000697 wat:InstrumentSystemsMember us-gaap:TransferredAtPointInTimeMember 2024-06-30 2024-09-28 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2024-06-30 2024-09-28 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2024-06-30 2024-09-28 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2024-06-30 2024-09-28 0001000697 us-gaap:RetainedEarningsMember 2024-06-30 2024-09-28 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 2024-09-28 0001000697 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 2024-09-28 0001000697 us-gaap:CommonStockMember 2024-06-30 2024-09-28 0001000697 us-gaap:TreasuryStockCommonMember 2024-06-30 2024-09-28 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:InterestIncomeMember 2024-06-30 2024-09-28 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestIncomeMember 2024-06-30 2024-09-28 0001000697 us-gaap:ServiceMember 2025-06-29 2025-09-27 0001000697 us-gaap:ProductMember 2025-06-29 2025-09-27 0001000697 wat:TaServiceMember 2025-06-29 2025-09-27 0001000697 wat:TaInstrumentSystemsMember 2025-06-29 2025-09-27 0001000697 wat:ChemistryConsumablesMember 2025-06-29 2025-09-27 0001000697 wat:WatersInstrumentSystemsMember 2025-06-29 2025-09-27 0001000697 wat:WatersServiceMember 2025-06-29 2025-09-27 0001000697 srt:AsiaPacificMember 2025-06-29 2025-09-27 0001000697 wat:AsiaOtherMember 2025-06-29 2025-09-27 0001000697 country:CN 2025-06-29 2025-09-27 0001000697 srt:AmericasMember 2025-06-29 2025-09-27 0001000697 wat:AmericasOtherMember 2025-06-29 2025-09-27 0001000697 country:US 2025-06-29 2025-09-27 0001000697 srt:EuropeMember 2025-06-29 2025-09-27 0001000697 wat:GovernmentalAndAcademicCustomersMember 2025-06-29 2025-09-27 0001000697 wat:PharmaceuticalCustomersMember 2025-06-29 2025-09-27 0001000697 wat:IndustrialCustomersMember 2025-06-29 2025-09-27 0001000697 wat:ChemistryConsumablesMember us-gaap:TransferredAtPointInTimeMember 2025-06-29 2025-09-27 0001000697 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2025-06-29 2025-09-27 0001000697 us-gaap:TransferredAtPointInTimeMember 2025-06-29 2025-09-27 0001000697 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2025-06-29 2025-09-27 0001000697 us-gaap:TransferredOverTimeMember 2025-06-29 2025-09-27 0001000697 wat:InstrumentSystemsMember us-gaap:TransferredAtPointInTimeMember 2025-06-29 2025-09-27 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2025-06-29 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2025-06-29 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2025-06-29 2025-09-27 0001000697 us-gaap:RetainedEarningsMember 2025-06-29 2025-09-27 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-29 2025-09-27 0001000697 us-gaap:AdditionalPaidInCapitalMember 2025-06-29 2025-09-27 0001000697 us-gaap:CommonStockMember 2025-06-29 2025-09-27 0001000697 us-gaap:TreasuryStockCommonMember 2025-06-29 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:InterestIncomeMember 2025-06-29 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestIncomeMember 2025-06-29 2025-09-27 0001000697 2024-12-31 2025-09-27 0001000697 2025-12-31 2025-09-27 0001000697 2026-12-31 2025-09-27 0001000697 us-gaap:OtherNoncurrentLiabilitiesMember 2025-09-27 0001000697 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember 2025-09-27 0001000697 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2025-09-27 0001000697 us-gaap:OtherAssetsMember wat:InterestRateSwapsCashFlowHedgesMember 2025-09-27 0001000697 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember 2025-09-27 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 us-gaap:ForeignExchangeContractMember 2025-09-27 0001000697 us-gaap:OtherLiabilitiesMember wat:InterestRateSwapsCashFlowHedgesMember 2025-09-27 0001000697 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember 2025-09-27 0001000697 us-gaap:OtherLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2025-09-27 0001000697 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-27 0001000697 us-gaap:UnsecuredDebtMember 2025-09-27 0001000697 us-gaap:TrademarksMember 2025-09-27 0001000697 wat:PurchasedIntangiblesMember 2025-09-27 0001000697 us-gaap:SoftwareDevelopmentMember 2025-09-27 0001000697 wat:PatentsAndOtherIntangiblesMember 2025-09-27 0001000697 us-gaap:LicensingAgreementsMember 2025-09-27 0001000697 wat:ForeignSubsidiaryMember 2025-09-27 0001000697 wat:InvestmentsHeldInCurrenciesOtherThanUSDollarsMember 2025-09-27 0001000697 us-gaap:NotesPayableToBanksMember 2025-09-27 0001000697 wat:CreditAgreementsAndUnsecuredDebtMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesKMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesLMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesNMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesQMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesMMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesOMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesPMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesLOneMember 2025-09-27 0001000697 wat:SeniorUnsecuredNotesSeriesKOneMember 2025-09-27 0001000697 wat:CreditAgreementMember 2025-09-27 0001000697 wat:FixedInterestRateMember us-gaap:UnsecuredDebtMember 2025-09-27 0001000697 srt:MinimumMember 2025-12-31 2025-09-27 0001000697 srt:MaximumMember 2025-12-31 2025-09-27 0001000697 wat:WyattMember 2025-09-27 0001000697 wat:TwoThousandAndTwentyOneCreditFacilityMember 2025-09-27 0001000697 wat:BDBiosciencesAndDiagnosticSolutionsMember 2025-09-27 0001000697 wat:VariableInterestRateCashFlowHedgeMember 2025-09-27 0001000697 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31 0001000697 us-gaap:OtherAssetsMember us-gaap:CrossCurrencyInterestRateContractMember 2024-12-31 0001000697 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2024-12-31 0001000697 us-gaap:OtherAssetsMember wat:InterestRateSwapsCashFlowHedgesMember 2024-12-31 0001000697 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 wat:InterestRateSwapsCashFlowHedgesMember 2024-12-31 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 us-gaap:CrossCurrencyInterestRateContractMember 2024-12-31 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 us-gaap:ForeignExchangeContractMember 2024-12-31 0001000697 us-gaap:OtherLiabilitiesMember wat:InterestRateSwapsCashFlowHedgesMember 2024-12-31 0001000697 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember 2024-12-31 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2024-12-31 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2024-12-31 0001000697 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001000697 us-gaap:UnsecuredDebtMember 2024-12-31 0001000697 wat:PurchasedIntangiblesMember 2024-12-31 0001000697 us-gaap:SoftwareDevelopmentMember 2024-12-31 0001000697 wat:PatentsAndOtherIntangiblesMember 2024-12-31 0001000697 us-gaap:LicensingAgreementsMember 2024-12-31 0001000697 us-gaap:TrademarksMember 2024-12-31 0001000697 wat:InvestmentsHeldInCurrenciesOtherThanUSDollarsMember 2024-12-31 0001000697 wat:ForeignSubsidiaryMember 2024-12-31 0001000697 us-gaap:NotesPayableToBanksMember 2024-12-31 0001000697 wat:CreditAgreementsAndUnsecuredDebtMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesMMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesNMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesOMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesPMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesQMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesKMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesLMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesLOneMember 2024-12-31 0001000697 wat:SeniorUnsecuredNotesSeriesKOneMember 2024-12-31 0001000697 wat:CreditAgreementMember 2024-12-31 0001000697 wat:FixedInterestRateMember us-gaap:UnsecuredDebtMember 2024-12-31 0001000697 wat:January2019ProgramMember 2024-12-31 0001000697 wat:TwoThousandAndTwentyOneCreditFacilityMember 2024-12-31 0001000697 us-gaap:ServiceMember 2024-01-01 2024-09-28 0001000697 us-gaap:ProductMember 2024-01-01 2024-09-28 0001000697 wat:TaInstrumentSystemsMember 2024-01-01 2024-09-28 0001000697 wat:ChemistryConsumablesMember 2024-01-01 2024-09-28 0001000697 wat:WatersInstrumentSystemsMember 2024-01-01 2024-09-28 0001000697 wat:WatersServiceMember 2024-01-01 2024-09-28 0001000697 wat:TaServiceMember 2024-01-01 2024-09-28 0001000697 srt:EuropeMember 2024-01-01 2024-09-28 0001000697 srt:AsiaPacificMember 2024-01-01 2024-09-28 0001000697 wat:AsiaOtherMember 2024-01-01 2024-09-28 0001000697 country:CN 2024-01-01 2024-09-28 0001000697 srt:AmericasMember 2024-01-01 2024-09-28 0001000697 wat:AmericasOtherMember 2024-01-01 2024-09-28 0001000697 country:US 2024-01-01 2024-09-28 0001000697 wat:IndustrialCustomersMember 2024-01-01 2024-09-28 0001000697 wat:GovernmentalAndAcademicCustomersMember 2024-01-01 2024-09-28 0001000697 wat:PharmaceuticalCustomersMember 2024-01-01 2024-09-28 0001000697 us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-09-28 0001000697 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-09-28 0001000697 us-gaap:TransferredOverTimeMember 2024-01-01 2024-09-28 0001000697 wat:InstrumentSystemsMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-09-28 0001000697 wat:ChemistryConsumablesMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-09-28 0001000697 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2024-01-01 2024-09-28 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2024-01-01 2024-09-28 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2024-01-01 2024-09-28 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2024-01-01 2024-09-28 0001000697 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-28 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-28 0001000697 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-28 0001000697 us-gaap:CommonStockMember 2024-01-01 2024-09-28 0001000697 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-28 0001000697 wat:RelatedToVestingOfRestrictedStockUnitsMember 2024-01-01 2024-09-28 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:InterestIncomeMember 2024-01-01 2024-09-28 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestIncomeMember 2024-01-01 2024-09-28 0001000697 us-gaap:SettledLitigationMember 2024-01-01 2024-09-28 0001000697 us-gaap:ServiceMember 2025-01-01 2025-09-27 0001000697 us-gaap:ProductMember 2025-01-01 2025-09-27 0001000697 wat:TaInstrumentSystemsMember 2025-01-01 2025-09-27 0001000697 wat:ChemistryConsumablesMember 2025-01-01 2025-09-27 0001000697 wat:TaServiceMember 2025-01-01 2025-09-27 0001000697 wat:WatersServiceMember 2025-01-01 2025-09-27 0001000697 wat:WatersInstrumentSystemsMember 2025-01-01 2025-09-27 0001000697 country:CN 2025-01-01 2025-09-27 0001000697 country:US 2025-01-01 2025-09-27 0001000697 srt:AsiaPacificMember 2025-01-01 2025-09-27 0001000697 wat:AsiaOtherMember 2025-01-01 2025-09-27 0001000697 srt:EuropeMember 2025-01-01 2025-09-27 0001000697 srt:AmericasMember 2025-01-01 2025-09-27 0001000697 wat:AmericasOtherMember 2025-01-01 2025-09-27 0001000697 wat:GovernmentalAndAcademicCustomersMember 2025-01-01 2025-09-27 0001000697 wat:PharmaceuticalCustomersMember 2025-01-01 2025-09-27 0001000697 wat:IndustrialCustomersMember 2025-01-01 2025-09-27 0001000697 us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-27 0001000697 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-27 0001000697 us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-27 0001000697 wat:InstrumentSystemsMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-27 0001000697 wat:ChemistryConsumablesMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-27 0001000697 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-27 0001000697 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-01-01 2025-09-27 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-27 0001000697 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-09-27 0001000697 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-09-27 0001000697 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2025-01-01 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherComprehensiveIncomeMember 2025-01-01 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:OtherComprehensiveIncomeMember 2025-01-01 2025-09-27 0001000697 wat:NewContractualArrangementMember country:SG wat:AprilTwoThousandAndTwentyOneToMarchTwoThousandAndTwentySixMember 2025-01-01 2025-09-27 0001000697 country:IE 2025-01-01 2025-09-27 0001000697 country:GB 2025-01-01 2025-09-27 0001000697 country:SG 2025-01-01 2025-09-27 0001000697 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-27 0001000697 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-27 0001000697 us-gaap:CommonStockMember 2025-01-01 2025-09-27 0001000697 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-27 0001000697 wat:RelatedToVestingOfRestrictedStockUnitsMember 2025-01-01 2025-09-27 0001000697 wat:InterestRateSwapsCashFlowHedgesMember us-gaap:InterestIncomeMember 2025-01-01 2025-09-27 0001000697 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestIncomeMember 2025-01-01 2025-09-27 0001000697 wat:WyattMember 2025-01-01 2025-09-27 0001000697 us-gaap:SoftwareDevelopmentMember 2025-01-01 2025-09-27 0001000697 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-01-01 2025-09-27 0001000697 us-gaap:UnsecuredDebtMember srt:MinimumMember 2025-01-01 2025-09-27 0001000697 us-gaap:UnsecuredDebtMember srt:MaximumMember 2025-01-01 2025-09-27 0001000697 us-gaap:RevolvingCreditFacilityMember 2025-05-22 0001000697 us-gaap:LetterOfCreditMember 2025-05-22 2025-05-22 0001000697 us-gaap:RevolvingCreditFacilityMember 2025-05-22 2025-05-22 0001000697 wat:BDBiosciencesAndDiagnosticSolutionsMember 2025-07-13 2025-07-13 0001000697 wat:SpincoMember 2025-07-13 2025-07-13 0001000697 wat:WatersCorporationMember 2025-07-13 0001000697 wat:BDBiosciencesAndDiagnosticSolutionsMember 2025-07-13 0001000697 us-gaap:SubsequentEventMember 2025-10-31 0001000697 wat:HaloLabsLTDMember 2025-05-20 0001000697 wat:HaloLabsLTDMember 2025-05-20 2025-05-20 0001000697 us-gaap:RetainedEarningsMember 2024-06-29 0001000697 us-gaap:TreasuryStockCommonMember 2024-06-29 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 0001000697 us-gaap:CommonStockMember 2024-06-29 0001000697 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 0001000697 us-gaap:RetainedEarningsMember 2024-09-28 0001000697 us-gaap:TreasuryStockCommonMember 2024-09-28 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-28 0001000697 us-gaap:CommonStockMember 2024-09-28 0001000697 us-gaap:AdditionalPaidInCapitalMember 2024-09-28 0001000697 us-gaap:CommonStockMember 2025-06-28 0001000697 us-gaap:AdditionalPaidInCapitalMember 2025-06-28 0001000697 us-gaap:RetainedEarningsMember 2025-06-28 0001000697 us-gaap:TreasuryStockCommonMember 2025-06-28 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-28 0001000697 us-gaap:CommonStockMember 2025-09-27 0001000697 us-gaap:AdditionalPaidInCapitalMember 2025-09-27 0001000697 us-gaap:RetainedEarningsMember 2025-09-27 0001000697 us-gaap:TreasuryStockCommonMember 2025-09-27 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-27 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001000697 us-gaap:CommonStockMember 2023-12-31 0001000697 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001000697 us-gaap:RetainedEarningsMember 2023-12-31 0001000697 us-gaap:TreasuryStockCommonMember 2023-12-31 0001000697 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001000697 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0001000697 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0001000697 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001000697 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-09-27 0001000697 us-gaap:AccumulatedTranslationAdjustmentMember 2025-09-27 0001000697 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-09-27 0001000697 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001000697 us-gaap:CommonStockMember 2024-12-31 0001000697 us-gaap:RetainedEarningsMember 2024-12-31 0001000697 us-gaap:TreasuryStockCommonMember 2024-12-31 xbrli:shares iso4217:USD xbrli:pure utr:Month utr:Year wat:Segment iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXHANGE ACT OF 1934

For the quarterly period ended September 27, 2025
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to
.
Commission File Number:
001-14010
Waters Corporation
(Exact name of registrant as specified in its charter)

Delaware |  | 13-3668640
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

34 Maple Street
Milford, Massachusetts 01757
(Address, including zip code, of principal executive offices)
(
508)
478-2000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, par value $0.01 per share |  | WAT |  | New York Stock Exchange, Inc.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in
Rule 12b-2
of the Exchange Act.

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
|  |  |  | Emerging growth company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2
of the Act). Yes ☐ No☒
Indicate the number of shares outstanding of the registrant’s common stock as of October 31, 2025: 59,534,740

##### Table of Contents

WATERS CORPORATION AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

|  |  |  | Page |
PART I |  | FINANCIAL INFORMATION |  |  |  |
Item 1. |  | Financial Statements |  |  |  |
|  | Consolidated Balance Sheets (unaudited) as of September 27, 2025 and December 31, 2024 |  |  | 3 |
|  | Consolidated Statements of Operations (unaudited) for the three months ended September 27, 2025 and September 28, 2024 |  |  | 4 |
|  | Consolidated Statements of Operations (unaudited) for the nine months ended September 27, 2025 and September 28, 2024 |  |  | 5 |
|  | Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended September 27, 2025 and September 28, 2024 |  |  | 6 |
|  | Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 27, 2025 and September 28, 2024 |  |  | 7 |
|  | Consolidated Statements of Stockholders’ Equity (unaudited) for the three months ended September 27, 2025 and September 28, 2024 |  |  | 8 |
|  | Consolidated Statements of Stockholders’ Equity (unaudited) for the nine months ended September 27, 2025 and September 28, 2024 |  |  | 9 |
|  | Condensed Notes to Consolidated Financial Statements (unaudited) |  |  | 10 |
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  |  | 30 |
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  |  | 43 |
Item 4. |  | Controls and Procedures |  |  | 43 |
PART II |  | OTHER INFORMATION |  |  |  |
Item 1. |  | Legal Proceedings |  |  | 44 |
Item 1A. |  | Risk Factors |  |  | 44 |
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  |  | 45 |
Item 5. |  | Other Information |  |  | 46 |
Item 6. |  | Exhibits |  |  | 47 |
|  | Signature |  |  | 48 |

##### Table of Contents

Item 1: Financial Statements
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)

|  | September 27, 2025 |  |  | December 31, 2024 |
|  | (In thousands, except per share data) |
ASSETS |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 459,118 |  |  | $ | 325,355 |
Accounts receivable, net |  |  | 748,519 |  |  |  | 733,365 |
Inventories |  |  | 572,941 |  |  |  | 477,261 |
Other current assets |  |  | 138,612 |  |  |  | 133,130 |
Total current assets |  |  | 1,919,190 |  |  |  | 1,669,111 |
Property, plant and equipment, net |  |  | 636,964 |  |  |  | 651,200 |
Intangible assets, net |  |  | 570,773 |  |  |  | 567,906 |
Goodwill |  |  | 1,338,358 |  |  |  | 1,295,720 |
Operating lease assets |  |  | 76,426 |  |  |  | 74,193 |
Other assets |  |  | 320,853 |  |  |  | 295,665 |
Total assets |  | $ | 4,862,564 |  |  | $ | 4,553,795 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Notes payable |  | $ | 460,000 |  |  | $ | — |
Accounts payable |  |  | 115,728 |  |  |  | 99,931 |
Accrued employee compensation |  |  | 80,331 |  |  |  | 93,969 |
Deferred revenue and customer advances |  |  | 301,342 |  |  |  | 250,807 |
Current operating lease liabilities |  |  | 28,487 |  |  |  | 25,537 |
Accrued income taxes |  |  | 56,370 |  |  |  | 158,658 |
Accrued warranty |  |  | 11,569 |  |  |  | 11,602 |
Other current liabilities |  |  | 197,468 |  |  |  | 149,254 |
Total current liabilities |  |  | 1,251,295 |  |  |  | 789,758 |
Long-term liabilities: |  |  |  |  |  |  |  |
Long-term debt |  |  | 947,206 |  |  |  | 1,626,488 |
Long-term portion of retirement benefits |  |  | 47,744 |  |  |  | 44,611 |
Long-term income tax liabilities |  |  | 30,880 |  |  |  | 30,318 |
Long-term operating lease liabilities |  |  | 50,472 |  |  |  | 50,317 |
Other long-term liabilities |  |  | 204,274 |  |  |  | 183,796 |
Total long-term liabilities |  |  | 1,280,576 |  |  |  | 1,935,530 |
Total liabilities |  |  | 2,531,871 |  |  |  | 2,725,288 |
Commitments and contingencies (Notes 6, 7 and 9) |  |  |  |  |  |  |  |
Stockholders’ equity: |  |  |  |  |  |  |  |
Preferred stock, par value $0.01 per share, 5,000 shares authorized, none issued at September 27, 2025 and December 31, 2024 |  |  | — |  |  |  | — |
Common stock, par value $0.01 per share, 400,000 shares authorized, 163,138 and 162,962 shares issued, 59,525 and 59,388 shares outstanding at September 27, 2025 and December 31, 2024, respectively |  |  | 1,631 |  |  |  | 1,630 |
Additional paid-in capital |  |  | 2,396,477 |  |  |  | 2,341,298 |
Retained earnings |  |  | 10,206,070 |  |  |  | 9,788,655 |
Treasury stock, at cost, 103,613 and 103,574 shares at September 27, 2025 and December 31, 2024, respectively |  |  | (10,162,316 | ) |  |  | (10,147,793 | )
Accumulated other comprehensive loss |  |  | (111,169 | ) |  |  | (155,283 | )
Total stockholders’ equity |  |  | 2,330,693 |  |  |  | 1,828,507 |
Total liabilities and stockholders’ equity |  | $ | 4,862,564 |  |  | $ | 4,553,795 |

The accompanying notes are an integral part of the interim consolidated financial statements.
3

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

|  | Three Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |
|  | (In thousands, except per share data) |
Revenues: |  |  |  |  |  |  |  |
Product sales |  | $ | 499,964 |  |  | $ | 462,011 |
Service sales |  |  | 299,923 |  |  |  | 278,294 |
Total net sales |  |  | 799,887 |  |  |  | 740,305 |
Costs and operating expenses: |  |  |  |  |  |  |  |
Cost of product sales |  |  | 210,634 |  |  |  | 193,378 |
Cost of service sales |  |  | 117,172 |  |  |  | 108,277 |
Selling and administrative expenses |  |  | 214,229 |  |  |  | 169,097 |
Research and development expenses |  |  | 53,643 |  |  |  | 45,336 |
Purchased intangibles amortization |  |  | 12,095 |  |  |  | 11,759 |
Litigation provision |  |  | — |  |  |  | 1,326 |
Total costs and operating expenses |  |  | 607,773 |  |  |  | 529,173 |
Operating income |  |  | 192,114 |  |  |  | 211,132 |
Other expense, net |  |  | (70 | ) |  |  | (338 | )
Interest expense |  |  | (26,637 | ) |  |  | (21,435 | )
Interest income |  |  | 4,712 |  |  |  | 4,258 |
Income before income taxes |  |  | 170,119 |  |  |  | 193,617 |
Provision for income taxes |  |  | 21,196 |  |  |  | 32,114 |
Net income |  | $ | 148,923 |  |  | $ | 161,503 |
Net income per basic common share |  | $ | 2.50 |  |  | $ | 2.72 |
Weighted-average number of basic common shares |  |  | 59,528 |  |  |  | 59,367 |
Net income per diluted common share |  | $ | 2.50 |  |  | $ | 2.71 |
Weighted-average number of diluted common shares and equivalents |  |  | 59,622 |  |  |  | 59,504 |

The accompanying notes are an integral part of the interim consolidated financial statements.
4

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

|  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |
|  | (In thousands, except per share data) |
Revenues: |  |  |  |  |  |  |  |
Product sales |  | $ | 1,373,894 |  |  | $ | 1,273,306 |
Service sales |  |  | 859,030 |  |  |  | 812,367 |
Total net sales |  |  | 2,232,924 |  |  |  | 2,085,673 |
Costs and operating expenses: |  |  |  |  |  |  |  |
Cost of product sales |  |  | 579,686 |  |  |  | 522,396 |
Cost of service sales |  |  | 346,272 |  |  |  | 329,289 |
Selling and administrative expenses |  |  | 590,367 |  |  |  | 516,880 |
Research and development expenses |  |  | 148,813 |  |  |  | 136,113 |
Purchased intangibles amortization |  |  | 35,714 |  |  |  | 35,337 |
Litigation provision |  |  | — |  |  |  | 11,568 |
Total costs and operating expenses |  |  | 1,700,852 |  |  |  | 1,551,583 |
Operating income |  |  | 532,072 |  |  |  | 534,090 |
Other income, net |  |  | 778 |  |  |  | 1,619 |
Interest expense |  |  | (55,261 | ) |  |  | (70,681 | )
Interest income |  |  | 13,108 |  |  |  | 12,857 |
Income before income taxes |  |  | 490,697 |  |  |  | 477,885 |
Provision for income taxes |  |  | 73,282 |  |  |  | 71,449 |
Net income |  | $ | 417,415 |  |  | $ | 406,436 |
Net income per basic common share |  | $ | 7.02 |  |  | $ | 6.85 |
Weighted-average number of basic common shares |  |  | 59,496 |  |  |  | 59,314 |
Net income per diluted common share |  | $ | 7.00 |  |  | $ | 6.83 |
Weighted-average number of diluted common shares and equivalents |  |  | 59,656 |  |  |  | 59,471 |

The accompanying notes are an integral part of the interim consolidated financial statements.
5

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited)

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
|  | (In thousands) |  |  | (In thousands) |
Net income |  | $ | 148,923 |  |  | $ | 161,503 |  |  | $ | 417,415 |  |  | $ | 406,436 |
Other comprehensive income: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation |  |  | 5,595 |  |  |  | 18,668 |  |  |  | 45,863 |  |  |  | 2,453 |
Unrealized gains (losses) on derivative instruments before reclassifications |  |  | 90 |  |  |  | (3,025 | ) |  |  | (1,731 | ) |  |  | 209 |
Amounts reclassified to interest income |  |  | (120 | ) |  |  | (366 | ) |  |  | (431 | ) |  |  | (940 | )
Unrealized losses on derivative instruments before income taxes |  |  | (30 | ) |  |  | (3,391 | ) |  |  | (2,162 | ) |  |  | (731 | )
Income tax benefit |  |  | 7 |  |  |  | 814 |  |  |  | 519 |  |  |  | 176 |
Unrealized losses on derivative instruments, net of tax |  |  | (23 | ) |  |  | (2,577 | ) |  |  | (1,643 | ) |  |  | (555 | )
Retirement liability adjustment before reclassifications |  |  | 44 |  |  |  | (211 | ) |  |  | (7 | ) |  |  | (60 | )
Amounts reclassified to other income, net |  |  | (1 | ) |  |  | (10 | ) |  |  | (1 | ) |  |  | (68 | )
Retirement liability adjustment before income taxes |  |  | 43 |  |  |  | (221 | ) |  |  | (8 | ) |  |  | (128 | )
Income tax (expense) benefit |  |  | (13 | ) |  |  | 47 |  |  |  | (98 | ) |  |  | 65 |
Retirement liability adjustment, net of tax |  |  | 30 |  |  |  | (174 | ) |  |  | (106 | ) |  |  | (63 | )
Other comprehensive income |  |  | 5,602 |  |  |  | 15,917 |  |  |  | 44,114 |  |  |  | 1,835 |
Comprehensive income |  | $ | 154,525 |  |  | $ | 177,420 |  |  | $ | 461,529 |  |  | $ | 408,271 |

The accompanying notes are an integral part of the interim consolidated financial statements.
6

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

|  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |
|  | (In thousands) |
Cash flows from operating activities: |  |  |  |
Net income |  | $ | 417,415 |  |  | $ | 406,436 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |  |  |  |
Stock-based compensation |  |  | 39,625 |  |  |  | 32,993 |
Deferred income taxes |  |  | (17,274 | ) |  |  | (1,967 | )
Depreciation |  |  | 66,211 |  |  |  | 64,680 |
Amortization of intangibles |  |  | 87,485 |  |  |  | 78,570 |
Change in operating assets and liabilities: |  |  |  |  |  |  |  |
Decrease in accounts receivable |  |  | 26,122 |  |  |  | 27,457 |
Increase in inventories |  |  | (65,956 | ) |  |  | (2,032 | )
(Increase) decrease in other current assets |  |  | (9,753 | ) |  |  | 1,279 |
Decrease (increase) in other assets |  |  | 41,324 |  |  |  | (18,416 | )
(Decrease) increase in accounts payable and other current liabilities |  |  | (114,249 | ) |  |  | 36,485 |
Increase in deferred revenue and customer advances |  |  | 34,071 |  |  |  | 37,972 |
Decrease in other liabilities |  |  | (17,019 | ) |  |  | (141,473 | )
Net cash provided by operating activities |  |  | 488,002 |  |  |  | 521,984 |
Cash flows from investing activities: |  |  |  |  |  |  |  |
Additions to property, plant, equipment and software capitalization |  |  | (73,772 | ) |  |  | (90,377 | )
Business acquisitions, net of cash acquired |  |  | (35,053 | ) |  |  | — |
Investments in unaffiliated companies, net |  |  | (1,295 | ) |  |  | (1,489 | )
Purchases of investments |  |  | — |  |  |  | (2,796 | )
Maturities and sales of investments |  |  | — |  |  |  | 2,752 |
Net cash used in investing activities |  |  | (110,120 | ) |  |  | (91,910 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Proceeds from debt issuances |  |  | 70,000 |  |  |  | 170,000 |
Payments on debt |  |  | (290,000 | ) |  |  | (700,000 | )
Payments of debt issuance costs |  |  | (22,986 | ) |  |  | — |
Proceeds from stock plans |  |  | 15,621 |  |  |  | 25,073 |
Purchases of treasury shares |  |  | (14,523 | ) |  |  | (13,475 | )
Proceeds from derivative contracts |  |  | 1,347 |  |  |  | 15,305 |
Net cash used in financing activities |  |  | (240,541 | ) |  |  | (503,097 | )
Effect of exchange rate changes on cash and cash equivalents |  |  | (3,578 | ) |  |  | 8,461 |
Increase (decrease) in cash and cash equivalents |  |  | 133,763 |  |  |  | (64,562 | )
Cash and cash equivalents at beginning of period |  |  | 325,355 |  |  |  | 395,076 |
Cash and cash equivalents at end of period |  | $ | 459,118 |  |  | $ | 330,514 |

The accompanying notes are an integral part of the interim consolidated financial statements.
7

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited, in thousands)

|  | Number of Common Shares |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Treasury Stock |  |  | Accumulated Other Comprehensive Loss |  |  | Total Stockholders’ Equity |
Balance June 29, 2024 |  |  | 162,926 |  |  | $ | 1,629 |  |  | $ | 2,310,372 |  |  | $ | 9,395,754 |  |  | $ | (10,147,586 | ) |  | $ | (148,202 | ) |  | $ | 1,411,967 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 161,503 |  |  |  | — |  |  |  | — |  |  |  | 161,503 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 15,917 |  |  |  | 15,917 |
Issuance of common stock for employees: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Employee Stock Purchase Plan |  |  | 9 |  |  |  | — |  |  |  | 2,551 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,551 |
Stock options exercised |  |  | 4 |  |  |  | — |  |  |  | 736 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 736 |
Treasury stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (141 | ) |  |  | — |  |  |  | (141 | )
Stock-based compensation |  |  | 1 |  |  |  | — |  |  |  | 10,566 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 10,566 |
Balance September 28, 2024 |  |  | 162,940 |  |  | $ | 1,629 |  |  | $ | 2,324,225 |  |  | $ | 9,557,257 |  |  | $ | (10,147,727 | ) |  | $ | (132,285 | ) |  | $ | 1,603,099 |

|  | Number of Common Shares |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Treasury Stock |  |  | Accumulated Other Comprehensive Loss |  |  | Total Stockholders’ Equity |
Balance June 28, 2025 |  |  | 163,126 |  |  | $ | 1,631 |  |  | $ | 2,379,907 |  |  | $ | 10,057,147 |  |  | $ | (10,162,102 | ) |  | $ | (116,771 | ) |  | $ | 2,159,812 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 148,923 |  |  |  | — |  |  |  | — |  |  |  | 148,923 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5,602 |  |  |  | 5,602 |
Issuance of common stock for employees: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Employee Stock Purchase Plan |  |  | 9 |  |  |  | — |  |  |  | 2,821 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,821 |
Stock options exercised |  |  | — |  |  |  | — |  |  |  | 62 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 62 |
Treasury stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (214 | ) |  |  | — |  |  |  | (214 | )
Stock-based compensation |  |  | 3 |  |  |  | — |  |  |  | 13,687 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 13,687 |
Balance September 27, 2025 |  |  | 163,138 |  |  | $ | 1,631 |  |  | $ | 2,396,477 |  |  | $ | 10,206,070 |  |  | $ | (10,162,316 | ) |  | $ | (111,169 | ) |  | $ | 2,330,693 |

The accompanying notes are an integral part of the consolidated financial statements.
8

Table of Contents
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(unaudited, in thousands)

|  | Number of Common Shares |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Treasury Stock |  |  | Accumulated Other Comprehensive Loss |  |  | Total Stockholders’ Equity |
Balance December 31, 2023 |  |  | 162,709 |  |  | $ | 1,627 |  |  | $ | 2,266,265 |  |  | $ | 9,150,821 |  |  | $ | (10,134,252 | ) |  | $ | (134,120 | ) |  | $ | 1,150,341 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 406,436 |  |  |  | — |  |  |  | — |  |  |  | 406,436 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,835 |  |  |  | 1,835 |
Issuance of common stock for employees: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Employee Stock Purchase Plan |  |  | 27 |  |  |  | — |  |  |  | 7,341 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,341 |
Stock options exercised |  |  | 87 |  |  |  | 1 |  |  |  | 18,347 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 18,348 |
Treasury stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (13,475 | ) |  |  | — |  |  |  | (13,475 | )
Stock-based compensation |  |  | 117 |  |  |  | 1 |  |  |  | 32,272 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 32,273 |
Balance September 28, 2024 |  |  | 162,940 |  |  | $ | 1,629 |  |  | $ | 2,324,225 |  |  | $ | 9,557,257 |  |  | $ | (10,147,727 | ) |  | $ | (132,285 | ) |  | $ | 1,603,099 |

|  | Number of Common Shares |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Treasury Stock |  |  | Accumulated Other Comprehensive Loss |  |  | Total Stockholders’ Equity |
Balance December 31, 2024 |  |  | 162,962 |  |  | $ | 1,630 |  |  | $ | 2,341,298 |  |  | $ | 9,788,655 |  |  | $ | (10,147,793 | ) |  | $ | (155,283 | ) |  | $ | 1,828,507 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 417,415 |  |  |  | — |  |  |  | — |  |  |  | 417,415 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 44,114 |  |  |  | 44,114 |
Issuance of common stock for employees: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Employee Stock Purchase Plan |  |  | 26 |  |  |  | — |  |  |  | 8,413 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 8,413 |
Stock options exercised |  |  | 38 |  |  |  | — |  |  |  | 7,867 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,867 |
Treasury stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (14,523 | ) |  |  | — |  |  |  | (14,523 | )
Stock-based compensation |  |  | 112 |  |  |  | 1 |  |  |  | 38,899 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 38,900 |
Balance September 27, 2025 |  |  | 163,138 |  |  | $ | 1,631 |  |  | $ | 2,396,477 |  |  | $ | 10,206,070 |  |  | $ | (10,162,316 | ) |  | $ | (111,169 | ) |  | $ | 2,330,693 |

The accompanying notes are an integral part of the consolidated financial statements.
9

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1 Basis of Presentation and Summary of Significant Accounting Policies
Waters Corporation (the “Company,” “we,” “our,” or “us”), a global leader in analytical instruments and software, has pioneered innovations in chromatography, mass spectrometry and thermal analysis serving life, materials and food sciences for more than 65 years. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC” and together with HPLC, referred to as “LC”) and mass spectrometry (“MS”) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. These systems are complementary products that are frequently employed together
(“LC-MS”)
and sold as integrated instrument systems using common software platforms. LC is a standard technique and is utilized in a broad range of industries to detect, identify, monitor and measure the chemical, physical and biological composition of materials, and to purify a full range of compounds. MS technology, principally in conjunction with chromatography, is employed in drug discovery and development, including clinical trial testing, the analysis of proteins in disease processes (known as “proteomics”), nutritional safety analysis and environmental testing.
LC-MS
instruments combine a liquid phase sample introduction and separation system with mass spectrometric compound identification and quantification. In addition, the Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments product line. These instruments are used in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals and viscous liquids for various industrial, consumer goods and healthcare products, as well as for life science research. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.
The Company’s interim fiscal quarter typically ends on the thirteenth Saturday of each quarter. Since the Company’s fiscal year end is December 31, the first and fourth fiscal quarters may have more or less than thirteen complete weeks. The Company’s third fiscal quarters for 2025 and 2024 ended on September 27, 2025 and September 28, 2024, respectively.
The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the instructions in Form
10-Q
and do not include all of the information and footnote disclosures required for annual financial statements prepared in accordance with generally accepted accounting principles (“U.S. GAAP”) in the United States of America. The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned. All intercompany balances and transactions have been eliminated.
The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent liabilities at the dates of the financial statements. Actual amounts may differ from these estimates under different assumptions or conditions.
It is management’s opinion that the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form
10-K
for the year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 25, 2025.
Acquisition of BD Biosciences & Diagnostic Solutions Businesses
On July 13, 2025, the Company entered into a separation agreement ( the “Separation Agreement”) and a merger agreement (the “Merger Agreement”) to purchase and combine Becton, Dickinson and Company’s (“BD”) Biosciences and Diagnostic Solutions business with Waters Corporation (the “Merger”). The transaction is structured as a Reverse Morris Trust transaction, where BD’s Biosciences & Diagnostic Solutions business will be spun off to BD shareholders and simultaneously merged with a wholly owned subsidiary of the Company. The transaction is valued at approximately $17.5 billion as of the date of signing. BD’s shareholders are expected
10

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS
(unaudited) – (Continued)
to own approximately 39.2% of the combined company, and existing Waters Corporation shareholders are expected to own approximately 60.8% of the combined company. BD will receive a cash distribution of approximately $4 billion from SpinCo prior to the completion of the combination, subject to adjustment for cash, working capital and indebtedness. In order to fund this cash distribution, SpinCo is expected to incur $4 billion of new indebtedness prior to the completion of the combination, which indebtedness will be assumed by Waters upon completion of the combination. The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, Waters Corporation shareholder approval and satisfaction of other customary closing conditions.
The Merger Agreement also contains specified termination rights for the Company and BD, including a right allowing the Company or BD to terminate the Merger Agreement if the Merger has not been consummated on or prior to July 13, 2026 (which date may be extended to October 13, 2026 in the event that required regulatory approvals have not been received). Additionally, the Merger Agreement requires the Company to pay BD a termination fee of $733 million if the Merger Agreement is terminated under certain circumstances.
In connection with the Merger Agreement, the Company and a financial institution executed a 364-day bridge facility commitment letter, pursuant to which such financial institution has committed to provide bridge financing of $1.8 billion to fund dividends, fees and expenses related to the transactions contemplated by the Merger Agreement. The bridge facility is expected to be replaced with permanent financing, which may include a delayed draw term loan facility.
Risks and Uncertainties
The Company is subject to risks common to companies in the analytical instrument industry, including, but not limited to, global economic and financial market conditions, fluctuations in foreign currency exchange rates, fluctuations in customer demand, development by its competitors of new technological innovations, costs of developing new technologies, levels of debt and debt service requirements, risk of disruption, dependence on key personnel, protection and litigation of proprietary technology, shifts in taxable income between tax jurisdictions and compliance with new tariff rules and regulations of the U.S. Food and Drug Administration and similar foreign regulatory authorities and agencies.
Translation of Foreign Currencies
The functional currency of each of the Company’s foreign operating subsidiaries is the local currency of its country of domicile, except for the Company’s subsidiaries in Hong Kong and Singapore, where the underlying transactional cash flows are denominated in currencies other than the respective local currency of domicile. The functional currency of the Hong Kong and Singapore subsidiaries is the U.S. dollar, based on the respective entity’s cash flows.
For the Company’s foreign operations, assets and liabilities are translated into U.S. dollars at exchange rates prevailing on the balance sheet date, while revenues and expenses are translated at average exchange rates prevailing during the respective period. Any resulting translation gains or losses are included in accumulated other comprehensive loss in the consolidated balance sheets.
Cash and Cash Equivalents
Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of September 27, 2025 and December 31, 2024, $339 million out of $459 million and $275 million out of $325 million, respectively, of the Company’s total cash and cash equivalents were held by foreign subsidiaries. In addition, $285 million out of $459 million and $226 million out of $325 million of cash and cash equivalents were held in currencies other than the U.S. dollar at September 27, 2025 and December 31, 2024, respectively.
Accounts Receivable and Allowance for Credit Losses
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company has very limited use of rebates and other cash considerations payable to customers and, as a result, the transaction price determination does not have any material variable consideration. The Company does not consider there to be significant concentrations of credit risk with respect to trade receivables due to the short-term nature of the balances, the Company
11

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
having a large and diverse customer base, and the Company having a strong historical experience of collecting receivables with minimal defaults. As a result, credit risk is considered low across territories and trade receivables are considered to be a single class of financial asset. The allowance for credit losses is based on a number of factors and is calculated by applying a historical loss rate to trade receivable aging balances to estimate a general reserve balance along with an additional adjustment for any specific receivables with known or anticipated issues affecting the likelihood of recovery. Past due balances with a probability of default based on historical data as well as relevant available forward-looking information are included in the specific adjustment. The historical loss rate is reviewed on at least an annual basis and the allowance for credit losses is reviewed quarterly for any required adjustments. The Company does not have any off-balance sheet credit exposure related to its customers.
Trade receivables related to instrument sales are collateralized by the instrument that is sold. If there is a risk of default related to a receivable that is collateralized, then the fair value of the collateral is calculated and adjusted for the cost to
re-possess,
refurbish and
re-sell
the instrument. This adjusted fair value is compared to the receivable balance and the difference would be recorded as the expected credit loss.
The following is a summary of the activity of the Company’s allowance for credit losses for the nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Balance at Beginning of Period |  |  | Additions |  |  | Deductions and Other |  |  | Balance at End of Period |
Allowance for Credit Losses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 27, 2025 |  | $ | 14,269 |  |  | $ | 3,797 |  |  | $ | (5,549 | ) |  | $ | 12,517 |
September 28, 2024 |  | $ | 19,335 |  |  | $ | 4,109 |  |  | $ | (7,451 | ) |  | $ | 15,993 |

Fair Value Measurements
In accordance with the accounting standards for fair value measurements and disclosures, certain of the Company’s assets and liabilities are measured at fair value on a recurring basis as of September 27, 2025 and December 31, 2024. Fair values determined by Level 1 inputs utilize observable data, such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the reporting entity to develop its own assumptions.
12

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at September 27, 2025 (in thousands):

|  | Total at September 27, 2025 |  |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Waters 401(k) Restoration Plan assets |  | $ | 31,494 |  |  | $ | 31,494 |  |  | $ | — |  |  | $ | — |
Foreign currency exchange contracts |  |  | 146 |  |  |  | — |  |  |  | 146 |  |  |  | — |
Interest rate cross-currency swap agreements |  |  | 130 |  |  |  | — |  |  |  | 130 |  |  |  | — |
Interest rate swap cash flow hedge |  |  | 122 |  |  |  | — |  |  |  | 122 |  |  |  | — |
Total |  | $ | 31,892 |  |  | $ | 31,494 |  |  | $ | 398 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency exchange contracts |  | $ | 542 |  |  | $ | — |  |  | $ | 542 |  |  | $ | — |
Interest rate cross-currency swap agreements |  |  | 50,643 |  |  |  | — |  |  |  | 50,643 |  |  |  | — |
Interest rate swap cash flow hedge |  |  | 2,423 |  |  |  | — |  |  |  | 2,423 |  |  |  | — |
Total |  | $ | 53,608 |  |  | $ | — |  |  | $ | 53,608 |  |  | $ | — |

The following table represents the Company’s assets and liabilities measured at fair value on a recurring basis at December 31, 2024 (in thousands):

|  | Total at December 31, 2024 |  |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Waters 401(k) Restoration Plan assets |  | $ | 30,137 |  |  | $ | 30,137 |  |  | $ | — |  |  | $ | — |
Foreign currency exchange contracts |  |  | 482 |  |  |  | — |  |  |  | 482 |  |  |  | — |
Interest rate cross-currency swap agreements |  |  | 26,196 |  |  |  | — |  |  |  | 26,196 |  |  |  | — |
Interest rate swap cash flow hedge |  |  | 503 |  |  |  | — |  |  |  | 503 |  |  |  | — |
Total |  | $ | 57,318 |  |  | $ | 30,137 |  |  | $ | 27,181 |  |  | $ | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency exchange contracts |  | $ | 261 |  |  | $ | — |  |  | $ | 261 |  |  | $ | — |
Interest rate swap cash flow hedge |  |  | 641 |  |  |  | — |  |  |  | 641 |  |  |  | — |
Total |  | $ | 902 |  |  | $ | — |  |  | $ | 902 |  |  | $ | — |

Fair Value of 401(k) Restoration Plan Assets
The 401(k) Restoration Plan is a nonqualified defined contribution plan, and the assets were held in registered mutual funds and have been classified as Level 1. The fair values of the assets in the plan are determined through market and observable sources from daily quoted prices on nationally recognized securities exchanges.
Fair Value of Cash Equivalents, Foreign Currency Exchange Contracts, Interest Rate Cross-Currency Swap Agreements and Interest Rate Swap Cash Flow Hedges
1
3

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The fair values of the Company’s cash equivalents, foreign currency exchange contracts, interest rate cross-currency swap agreements and interest rate swap cash flow hedges are determined through market and observable sources and have been classified as Level 2. These assets and liabilities have been initially valued at the transaction price and subsequently valued, typically utilizing third-party pricing services. The pricing services use many inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, current spot rates and other industry and economic events. The Company validates the prices provided by third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources.
Fair Value of Other Financial Instruments
The Company’s accounts receivable and accounts payable are recorded at cost, which approximates fair value due to their short-term nature. The carrying value of the Company’s variable interest rate debt approximates fair value due to the variable nature of the interest rate. The carrying value of the Company’s fixed interest rate debt was $1.3 billion at both September 27, 2025 and December 31, 2024. The fair value of the Company’s fixed interest rate debt was estimated using discounted cash flow models, based on estimated current rates offered for similar debt under current market conditions for the Company. The fair value of the Company’s fixed interest rate debt was estimated to be $1.2
billion and $1.1 billion at September 27, 2025 and December 31, 2024, respectively, using Level 2 inputs.
Derivative Transactions
The Company is a global company that operates in over 35 countries and, as a result, the Company’s net sales, cost of sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign currency exchange rates. The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its
non-U.S.
dollar foreign subsidiaries’ financial statements into U.S. dollars and when any of the Company’s subsidiaries purchase or sell products or services in a currency other than its own currency.
The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its euro-denominated and
yen-denominated
net asset investments. The Company presents the derivative transactions in financing activities in the statement of cash flows.
Foreign Currency Exchange Contracts
The Company does not specifically enter into any derivatives that hedge foreign-currency-denominated operating assets, liabilities or commitments on its balance sheet, other than a portion of certain third-party accounts receivable and accounts payable, and the Company’s net worldwide intercompany receivables and payables, which are eliminated in consolidation. The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balance to minimize some of the Company’s currency price risk exposure. The foreign currency exchange contracts are not designated for hedge accounting treatment. Principal hedged currencies include the euro, Japanese yen, British pound, Mexican peso and Brazilian real.
Cash Flow Hedges
The Company’s Credit Facility is a variable borrowing and has interest payments based on a contractually specified interest rate index. The contractually specified index on the Credit Facility is the 1-month, 3-month or 6-month Term SOFR. The variable rate interest payments create interest risk for the Company as interest payments will fluctuate based on changes in the contractually specified interest rate index over the life of the Credit Facility. In order to reduce interest rate risk, the Company has entered into interest rate swaps with an aggregate notional value of $
150
million to effectively lock in the forecasted interest payments on the variable rate borrowing over its term. The interest rate swaps represent cash flow hedges and are assessed for hedge effectiveness each reporting period. When the hedge relationship is highly effective at achieving offsetting changes in cash flows, the Company will record the entire change in fair value of the interest rate swaps in accumulated other comprehensive loss. The amount in accumulated other comprehensive loss is reclassified to income in the period that the underlying transaction impacts consolidated income. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated, and amounts accumulated in other comprehensive loss will be reclassified to income in the current period. Interest settlements due to benchmark interest rate changes are recorded in interest income or interest expense. For the nine months ended September 27, 2025, the Company did not have any cash flow hedges that were deemed ineffective.
14

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
Interest Rate Cross-Currency Swap Agreements
As of September 27, 2025, the Company had entered into interest rate cross-currency swap derivative agreements with durations up to three years with an aggregate notional value of $730 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its euro-denominated and
yen-denominated
net asset investments. Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in other comprehensive income and remain in accumulated other comprehensive loss in stockholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate cross-currency swap derivative agreement is recorded in interest income in the statement of operations.
The Company’s foreign currency exchange contracts, interest rate cross-currency swap agreements and interest rate swap agreements designated as cash flow hedges included in the consolidated balance sheets are classified as follows (in thousands):

|  | September 27, 2025 |  |  | December 31, 2024 |
|  | Notional Value |  |  | Fair Value |  |  | Notional Value |  |  | Fair Value |
Foreign currency exchange contracts: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  | $ | 18,499 |  |  | $ | 146 |  |  | $ | 14,999 |  |  | $ | 482 |
Other current liabilities |  | $ | 49,757 |  |  | $ | 542 |  |  | $ | 24,749 |  |  | $ | 261 |
Interest rate cross-currency swap agreements: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other assets |  | $ | 90,000 |  |  | $ | 130 |  |  | $ | 625,000 |  |  | $ | 26,196 |
Other liabilities |  | $ | 640,000 |  |  | $ | 50,643 |  |  | $ | — |  |  | $ | — |
Accumulated other comprehensive (loss) income |  |  |  |  |  | $ | (49,937 | ) |  |  |  |  |  | $ | 32,979 |
Interest rate swap cash flow hedges: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other assets |  | $ | 50,000 |  |  | $ | 122 |  |  | $ | 100,000 |  |  | $ | 503 |
Other liabilities |  | $ | 100,000 |  |  | $ | 2,423 |  |  | $ | 50,000 |  |  | $ | 641 |
Accumulated other comprehensive (loss) income |  |  |  |  |  | $ | (2,301 | ) |  |  |  |  |  | $ | (138 | )

1
5

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The following is a summary of the activity included in the consolidated statements of operations and statements of comprehensive income related to the foreign currency exchange contracts, interest rate cross-currency swap agreements and interest rate swap agreements designated as cash flow hedges (in thousands):

|  |  |  |  | Three Months Ended |  |  | Nine Months Ended |
|  | Financial Statement Classification |  |  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Foreign currency exchange contracts: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Realized (losses) gains on closed contracts |  |  | Cost of sales |  |  | $ | (23 | ) |  | $ | (138 | ) |  | $ | (1,421 | ) |  | $ | 914 |
Unrealized (losses) gains on open contracts |  |  | Cost of sales |  |  |  | (922 | ) |  |  | (26 | ) |  |  | (618 | ) |  |  | 39 |
Cumulative net pre-tax (losses) gains |  |  | Cost of sales |  |  | $ | (945 | ) |  | $ | (164 | ) |  | $ | (2,039 | ) |  | $ | 953 |
Interest rate cross-currency swap agreements: |  |  |  |  |  |  |  |  |  |  |  |  |
Interest earned |  |  | Interest income |  |  | $ | 3,076 |  |  | $ | 2,486 |  |  | $ | 8,145 |  |  | $ | 7,613 |
Unrealized gains (losses) on open contracts |  |  | Other comprehensive income |  |  | $ | 471 |  |  | $ | (28,339 | ) |  | $ | (82,917 | ) |  | $ | (6,775 | )
Interest rate swap cash flow hedges: |  |  |  |  |  |  |  |  |  |  |  |  |
Interest earned |  |  | Interest income |  |  | $ | 120 |  |  | $ | 366 |  |  | $ | 431 |  |  | $ | 940 |
Unrealized losses on open contracts |  |  | Other comprehensive income |  |  | $ | (32 | ) |  | $ | (3,391 | ) |  | $ | (2,163 | ) |  | $ | (731 | )

Stockholders’ Equity
In December 2024, the Company’s Board of Directors authorized the extension of its existing share repurchase program through January 21, 2028. The Company’s remaining authorization is $1.0 billion. The Company did not make any open market share repurchases in 2025 or 2024. The Company repurchased $15 million and $13 million of common stock related to the vesting of restricted stock units during the nine months ended September 27, 2025 and September 28, 2024, respectively.
Product Warranty Costs
The Company accrues estimated product warranty costs at the time of sale, which are included in cost of sales in the consolidated statements of operations. While the Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its component suppliers, the Company’s warranty obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. The amount of the accrued warranty liability is based on historical information, such as past experience, product failure rates, number of units repaired and estimated costs of material and labor. The liability is reviewed for reasonableness at least quarterly.
1
6

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The following is a summary of the activity of the Company’s accrued warranty liability for the nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Balance at Beginning of Period |  |  | Accruals for Warranties |  |  | Settlements Made |  |  | Balance at End of Period |
Accrued warranty liability: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
September 27, 2025 |  | $ | 11,602 |  |  | $ | 4,658 |  |  | $ | (4,691 | ) |  | $ | 11,569 |
September 28, 2024 |  | $ | 12,050 |  |  | $ | 3,812 |  |  | $ | (5,371 | ) |  | $ | 10,491 |

Subsequent Event
In October 2025, the Company entered into a derivative agreement with a duration up to two years, and a notional value of $50 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its euro-denominated net asset investments. The Company expects to designate the derivative as an interest rate cross-currency swap under hedge accounting.
1
7

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
2 Revenue Recognition
The Company’s deferred revenue liabilities in the consolidated balance sheets consist of the obligation on instrument service contracts and customer payments received in advance, prior to transfer of control of the instrument. The Company records deferred revenue primarily related to its service contracts, where consideration is billable at the beginning of the service period.
The following is a summary of the activity of the Company’s deferred revenue and customer advances for the nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | September 27, 2025 |  |  | September 28, 2024 |
Balance at the beginning of the period |  | $ | 320,046 |  |  | $ | 323,516 |
Recognition of revenue included in balance at beginning of the period |  |  | (248,970 | ) |  |  | (242,302 | )
Revenue deferred during the period, net of revenue recognized |  |  | 310,445 |  |  |  | 276,515 |
Balance at the end of the period |  | $ | 381,521 |  |  | $ | 357,729 |

The Company classified $80 million and $69 million of deferred revenue and customer advances in other long-term liabilities at September 27, 2025 and December 31, 2024, respectively.
The amount of unfulfilled performance obligations as of September 27, 2025, and the time such amounts are expected to be recognized in the future, is as follows (in thousands):

|  | September 27, 2025 |
Unfulfilled performance obligations expected to be recognized in: |  |  |  |
One year or less |  | $ | 311,609 |
13- 24 months |  |  | 41,867 |
25 months and beyond |  |  | 38,312 |
Total |  | $ | 391,788 |

3 Inventories
Inventories are classified as follows (in thousands):

|  | September 27, 2025 |  |  | December 31, 2024 |
Raw materials |  | $ | 241,957 |  |  | $ | 227,032 |
Work in progress |  |  | 33,907 |  |  |  | 21,801 |
Finished goods |  |  | 297,077 |  |  |  | 228,428 |
Total inventories |  | $ | 572,941 |  |  | $ | 477,261 |

4 Acquisitions
On May 20, 2025, the Company acquired all of the outstanding equity interests of Optofluidics, Inc., and its wholly owned operating subsidiary, Halo Labs LTD (collectively, “Halo Labs”), for $35 million, net of cash acquired. Halo Labs offers high throughput biopharmaceutical formulation, stability and product quality control tools for aggregate and subvisible particle analysis through the use of custom optics and image processing techniques. As a result of the acquisition, the results of Halo Labs are included in the Company’s consolidated financial statements from the acquisition date.
1
8

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The Company preliminarily allocated $13 million of the purchase price to intangible assets comprised of developed technology and customer relationships. The developed technology will be amortized over ten years, and the customer relationships will be amortized over five years. The Company allocated $24 million of the purchase price to goodwill, which is not deductible for tax purposes and has been allocated to the Waters operating segment. The principal factor that resulted in recognition of goodwill in the acquisition was that the purchase price was based, in part, on cash flow projections assuming the integration of any acquired technology, distribution channels and products with the Company’s products, which are higher than if the acquired companies’ technology, customer access or products were utilized on a stand-alone basis. The final fair value of the net assets acquired may result in adjustments to these assets and liabilities, including goodwill.
The assets and liabilities acquired were valued with input from valuation specialists. The Company used various income-approach valuation techniques, which use Level 3 inputs, in determining the fair value of the assets and liabilities acquired. The following table presents the fair values as of the acquisition date of all of the assets and liabilities owned and recorded in connection with the acquisition of Halo Labs assumed on the closing date of May 20, 2025 (in thousands):

Purchase Price |
Cash paid |  | $ | 35,815 |
Less: cash acquired |  |  | (762 | )
Net cash consideration |  |  | 35,053 |
Identifiable Net Assets (Liabilities) Acquired |  |  |  |
Accounts receivable |  |  | 962 |
Inventory |  |  | 1,296 |
Prepaid, property, plant and equipment, operating lease and other assets |  |  | 2,415 |
Intangible assets |  |  | 13,400 |
Accounts payable and accrued expenses |  |  | (1,966 | )
Operating lease liabilities, deferred revenue and other liabilities |  |  | (2,004 | )
Tax liabilities |  |  | (2,821 | )
Total identifiable net assets acquired |  |  | 11,282 |
Goodwill |  |  | 23,771 |
Net cash consideration |  | $ | 35,053 |

During the three and nine months ended September 27, 2025, the effect of net sales, net operating loss, and transaction related costs were immaterial to the Company’s consolidated results. The pro forma effect on the ongoing operations of the Company as though this acquisition had occurred on January 1, 2024 was immaterial to the consolidated financial statements.
5 Goodwill and Other Intangibles
The carrying amount of goodwill was $1.3 billion at both September 27, 2025 and December 31, 2024.
1
9

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The Company’s intangible assets included in the consolidated balance sheets are detailed as follows (dollars in thousands):

|  | September 27, 2025 |  | December 31, 2024 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Weighted- Average Amortization Period |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Weighted- Average Amortization Period |
Capitalized software |  | $ | 779,863 |  |  | $ | 609,403 |  |  | 5 years |  | $ | 662,085 |  |  | $ | 508,339 |  |  |  | 5 years |
Purchased intangibles |  |  | 631,707 |  |  |  | 283,239 |  |  | 10 years |  |  | 610,351 |  |  |  | 241,093 |  |  |  | 10 years |
Trademarks |  |  | 9,680 |  |  |  | — |  |  |  |  |  | 9,680 |  |  |  | — |  |  |  |  |  |  |  |  |
Licenses |  |  | 15,561 |  |  |  | 11,354 |  |  | 7 years |  |  | 14,549 |  |  |  | 9,628 |  |  |  | 7 years |
Patents and other intangibles |  |  | 133,464 |  |  |  | 95,506 |  |  | 8 years |  |  | 117,781 |  |  |  | 87,480 |  |  |  | 8 years |
Total |  | $ | 1,570,275 |  |  | $ | 999,502 |  |  | 7 years |  | $ | 1,414,446 |  |  | $ | 846,540 |  |  |  | 7 years |

The Company capitalized intangible assets in the amounts of $17 million and $11 million in the three months ended September 27, 2025 and September 28, 2024, respectively, and $69 million and $31 million in the nine months ended September 27, 2025 and September 28, 2024, respectively.
The gross carrying value of intangible assets and accumulated amortization for intangible assets increased by $87 million and $66 million, respectively, in the nine months ended September 27, 2025 due to the effects of foreign currency translation.
Amortization expense for intangible assets was $30 million and $28 million for the three months ended September 27, 2025 and September 28, 2024, respectively. Amortization expense for intangible assets was $87 million and $79 million for the nine months ended September 27, 2025 and September 28, 2024, respectively. Amortization expense for intangible assets is estimated to be $119 million per year for each of the next five years.
6 Debt
On May 22, 2025, the Company and certain of its subsidiaries, as guarantors, entered into an Amendment and Restatement Agreement (the “Amendment”) in respect of that certain Amended and Restated Credit Agreement, dated as of September 17, 2021 and amended as of March 3, 2023 (the “Existing Credit Agreement”, and as amended by the Amendment, the “Amended Credit Agreement”), with the lenders and issuing banks party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, pursuant to which the Company, among other things, reduced the aggregate total borrowing capacity of its existing senior unsecured revolving credit facility (the “Credit Facility”) by up to $200 million for an aggregate principal amount of up to $1.8 billion. As of September 27, 2025 and December 31, 2024, the Credit Facility had a total of $0.2 billion and $0.4 billion outstanding, respectively.
The Credit Facility will mature on May 22, 2030 subject to the Company’s ability to request, subject to customary conditions, a
one-year
extension to which each lender may, in its discretion, agree. The Company may, subject to customary conditions, also request additional incremental revolving or term loan commitments from the lenders in an aggregate principal amount not to exceed $750 million to which each lender may, in its discretion, agree, provided that the aggregate amount of all commitments, including any such incremental commitments, under the Amended Credit Agreement does not exceed $2.55 billion at any time. Up to $50 million of the Credit Facility is available in the form of letters of credit.
Interest on borrowings under the Credit Facility will accrue at an applicable rate equal to either Term SOFR plus an applicable spread or an alternate base rate plus an applicable spread, in each case based on the lower of the applicable rates determined as set forth in the Amended Credit Agreement based on the Company’s leverage ratio (determined as of the end of the most recent fiscal quarter for which financial statements have been delivered pursuant to the Amended Credit Agreement) or, when established, the Company’s public debt ratings by certain credit rating agencies applicable on such date. These applicable spreads range from 80 basis points to 112.5 basis points over Term SOFR and 0 basis points to 12.5 basis points over the alternate base rate, in each case, as determined in accordance with the
20

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
provisions of the Amended Credit Agreement. The Company has agreed to pay a facility fee at specified rates as set forth in the Amended Credit Agreement based on either its leverage ratio (determined as of the end of the most recent fiscal quarter for which financial statements have been delivered pursuant to the Amended Credit Agreement) or the Company’s public debt ratings applicable on such date, as applicable, ranging from 7.5 basis points to 22.5 basis points per annum, on the aggregate commitments of the lenders. The facility fee is payable on a quarterly basis. The Company has the right to prepay borrowings under the Credit Facility at any time, in whole or in part and without premium or penalty (other than, if applicable, any breakage costs). The Company may also reduce its commitments under the Credit Facility at any time.
The Company may use borrowings under the Credit Facility, which may be in United States dollars or the euro equivalent thereof, for general corporate purposes including repayment of debt, financing of acquisitions, payment of related fees and expenses, equity repurchases and working capital.
The Amended Credit Agreement contains affirmative and negative covenants, including limitations on subsidiary
debt
, liens, sale and leaseback transactions, mergers and certain restrictive agreements, as well as a financial covenant to not permit a leverage ratio as of the end of any fiscal quarter to exceed 3.50 to 1.00 (which may be increased to 4.25 to 1.00 at the Company’s election as of the last day of the fiscal quarter during which the Company’s closing of a material acquisition for which the aggregate consideration involves cash in the amount of $500 million or more) and a financial covenant to not permit an interest coverage ratio as of the end of any fiscal quarter for the period of four consecutive fiscal quarters then ended to be less than 3.50 to 1.00. The Credit Facility contains certain representations, warranties and events of default (which are, in some cases, subject to certain exceptions, thresholds and grace periods) including, but not limited to,
non-payment
of principal and interest, failure to perform or observe covenants, breaches of representations and warranties and certain bankruptcy-related events.
As of both September 27, 2025 and December 31, 2024, the Company had a total of $1.3 billion of outstanding senior unsecured notes. Interest on the fixed rate senior unsecured notes is payable semi-annually each year. The Company may prepay all or some of the senior unsecured notes at any time in an amount not less than 10% of the aggregate principal amount outstanding. In the event of a change in control of the Company (as defined in the note purchase agreement), the Company may be required to prepay the senior unsecured notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest. These senior unsecured notes require that the Company comply with an interest coverage ratio test of not less than 3.50:1 for any period of four consecutive fiscal quarters and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, these senior unsecured notes include customary negative covenants, affirmative covenants, representations and warranties and events of default.
Concurrently with the execution of the Merger Agreement, the Company and a financial institution executed a 364-day bridge facility commitment letter, pursuant to which such financial institution has committed to provide bridge financing of $1.8 billion to fund dividends, fees and expenses related to the transactions contemplated by the Merger Agreement, on the terms and conditions set forth therein. As of September 27, 2025, no amounts related to the bridge facility have been drawn.
The bridge facility is expected to be replaced with permanent financing, which may include a delayed draw term loan facility.
The Company incurred $5 million of financing costs that are being amortized over the term of the bridge facility. In addition, in connection with the Merger, the Company paid $14 million of financing costs on behalf of SpinCo. These financing costs were expensed in the three and nine months ended September 27, 2025.
21

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The Company had the following outstanding debt at September 27, 2025 and December 31, 2024 (in thousands):

|  | September 27, 2025 |  |  | December 31, 2024 |
Senior unsecured notes - Series K - 3.44%, due May 2026 |  | $ | 160,000 |  |  | $ | — |
Senior unsecured notes - Series L - 3.31%, due September 2026 |  |  | 200,000 |  |  |  | — |
Senior unsecured notes - Series N - 1.68%, due March 2026 |  |  | 100,000 |  |  |  | — |
Total notes payable and debt, current |  |  | 460,000 |  |  |  | — |
Senior unsecured notes - Series K - 3.44%, due May 2026 |  |  | — |  |  |  | 160,000 |
Senior unsecured notes - Series L - 3.31%, due September 2026 |  |  | — |  |  |  | 200,000 |
Senior unsecured notes - Series M - 3.53%, due September 2029 |  |  | 300,000 |  |  |  | 300,000 |
Senior unsecured notes - Series N - 1.68%, due March 2026 |  |  | — |  |  |  | 100,000 |
Senior unsecured notes - Series O - 2.25%, due March 2031 |  |  | 400,000 |  |  |  | 400,000 |
Senior unsecured notes - Series P - 4.91%, due May 2028 |  |  | 50,000 |  |  |  | 50,000 |
Senior unsecured notes - Series Q - 4.91%, due May 2030 |  |  | 50,000 |  |  |  | 50,000 |
Credit agreement |  |  | 150,000 |  |  |  | 370,000 |
Unamortized debt issuance costs |  |  | (2,794 | ) |  |  | (3,512 | )
Total long-term debt |  |  | 947,206 |  |  |  | 1,626,488 |
Total debt |  | $ | 1,407,206 |  |  | $ | 1,626,488 |

As of both September 27, 2025 and December 31, 2024, the Company had a total amount available to borrow under the Credit Facility of $1.6 billion after outstanding letters of credit. The weighted-average interest rates applicable to the senior unsecured notes and credit agreement borrowings collectively were 3.39% and 3.72% at September 27, 2025 and December 31, 2024, respectively. As of September 27, 2025, the Company was in compliance with all debt covenants.
The Company and its foreign subsidiaries also had available short-term lines of credit totaling $110 million and $111 million at September 27, 2025 and December 31, 2024, respectively, for the purpose of short-term borrowing and issuance of commercial guarantees. None of the Company’s foreign subsidiaries had outstanding short-term borrowings as of September 27, 2025 or December 31, 2024.
7 Income Taxes
The four principal jurisdictions in which the Company manufactures are the U.S., Ireland, the U.K. and Singapore, where the statutory tax rates were 21%, 12.5%, 25% and 17%, respectively, as of September 27, 2025. The Company has a Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% on certain types of income for the period April 1, 2021 through March 31, 2026. The effect of applying the concessionary income tax rate rather than the statutory tax rate to income arising from qualifying activities in Singapore increased the Company’s net income for the nine months ended September 27, 2025 and September 28, 2024 by $2 million and $9 million, respectively, and increased the Company’s net income per diluted share by $0.03 and $0.15, respectively.
The Company’s effective tax rate for the three months ended September 27, 2025 and September 28, 2024 was 12.5% and 16.6
%, respectively. The decrease between the effective tax rates can be primarily attributed to the impact of discrete tax benefits in the current year and differences in the proportionate amounts of pre-tax income recognized in jurisdictions with different effective tax rates.
The Company’s effective tax rate for the nine months ended September 27, 2025 and September 28, 2024 was 14.9% and 15.0
%, respectively. The decrease between the effective tax rates can primarily be attributed to the impact of differences in the proportionate amounts of pre-tax income recognized in jurisdictions with different effective tax rates.
The Company accounts for its uncertain tax return positions in accordance with the accounting standards for income taxes, which require financial statement reporting of the expected future tax consequences of uncertain tax reporting positions on the presumption that all concerned tax authorities possess full knowledge of those tax reporting positions,
22

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
as well as all of the pertinent facts and circumstances, but prohibit any discounting of unrecognized tax benefits associated with those reporting positions for the time value of money. The Company continues to classify interest and penalties related to unrecognized tax benefits as a component of the provision for income taxes.
The Company’s gross unrecognized tax benefits, excluding interest and penalties, at September 27, 2025 and September 28, 2024 were $18 million and $15 million, respectively. With limited exceptions, the Company is no longer subject to tax audit examinations in significant jurisdictions for the years ended on or before December 31, 2019. The Company continuously monitors the lapsing of statutes of limitations on potential tax assessments for related changes in the measurement of unrecognized tax benefits, related net interest and penalties, and deferred tax assets and liabilities.
Effective in 2024, various foreign jurisdictions began implementing aspects of the guidance issued by the Organization for
Economic Co-operation and
Development related to the new Pillar Two system of global minimum tax rules. These changes in tax law did not have a material impact on the Company’s financial position, results of operations and cash flows for the three and nine months ended September 27, 2025. The Company continues to monitor the adoption of the Pillar Two rules in additional jurisdictions.
On July 4, 2025, the U.S. government ena
cte
d the One Big Beautiful Tax Bill Act (“OBBB”), enacting changes to the United States federal tax code, including adjustments to effective tax rates on certain types of income and certain deduction limitations. The OBBB did not have a material impact on the Company’s financial position, results of operations and cash flows for the three and nine months ended September 27, 2025. The Company will continue to monitor the impact of the OBBB in future periods.
8 Litigation
From time to time, the Company and its subsidiaries are involved in various litigation matters arising in the ordinary course of business. The Company believes it has meritorious arguments in its current litigation matters and believes any outcome, either individually or in the aggregate, will not be material to the Company’s financial position, results of operations or cash flows. During the nine months ended September 28, 2024, the Company recorded $12 million and paid $10 million of patent litigation settlement provisions and related costs. No litigation provisions were recorded by the Company during the nine months ended September 27, 2025.
9 Other Commitments and Contingencies
The Company licenses certain technology and software from third parties in the ordinary course of business. Future minimum fees payable under existing technology and software license agreements as of September 27, 2025 are $
74
million for the years ended December 31, 2025 and thereafter. The software license agreements are long-term contracts and are not cancellable by the Company until the expiration of their initial term. The amounts owed under these contracts are included in both other assets and other long-term liabilities on the Company’s consolidated balance sheet as of September 27, 2025. In December 2024, the Company’s Board of Directors approved the implementation of a new worldwide enterprise resource planning system (“ERP”). The Company anticipates spending approximately $130 million on the ERP implementation over the next three years. The Company expects to use existing cash and its credit facility to fund the ERP implementation. For the nine months ended September 27, 2025, the Company has incurred $20 million of capitalized costs included in other assets and $14 million of operating costs included in the consolidated statement of operations for the ERP system implementation.
The Company enters into standard indemnification agreements in its ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with patent, copyright or other intellectual property infringement claims by any third party with respect to its current products, as well as claims relating to property damage or personal injury resulting from the performance of services by the Company or its subcontractors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, the Company’s costs to defend lawsuits or settle claims relating to such indemnity agreements have been minimal and management accordingly believes the estimated fair value of these agreements is immaterial.
2
3

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The Merger Agreement related to BD’s Biosciences & Diagnostic Solutions business contains specified termination rights that requires the Company to pay BD a termination fee of $733 million if the Merger Agreement is terminated under certain circumstances.
In addition, in connection with the Merger, the Company has incurred approximately $50 million of transaction-related expenses and financing costs through September 27, 2025. Based on information available through the date of this report, if the Merger closes, the Company estimates it will incur transaction-related expenses and financing fees of approximately $140 million in
total
.
10 Earnings Per Share
Basic and diluted EPS calculations are detailed as follows (in thousands, except per share data):

|  | Three Months Ended September 27, 2025 |
|  | Net Income (Numerator) |  |  | Weighted- Average Shares (Denominator) |  |  | Per Share Amount |
Net income per basic common share |  | $ | 148,923 |  |  |  | 59,528 |  |  | $ | 2.50 |
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities |  |  | — |  |  |  | 94 |  |  |  | — |
Net income per diluted common share |  | $ | 148,923 |  |  |  | 59,622 |  |  | $ | 2.50 |

|  | Three Months Ended September 28, 2024 |
|  | Net Income (Numerator) |  |  | Weighted- Average Shares (Denominator) |  |  | Per Share Amount |
Net income per basic common share |  | $ | 161,503 |  |  |  | 59,367 |  |  | $ | 2.72 |
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities |  |  | — |  |  |  | 137 |  |  |  | (0.01 | )
Net income per diluted common share |  | $ | 161,503 |  |  |  | 59,504 |  |  | $ | 2.71 |

|  | Nine Months Ended September 27, 2025 |
|  | Net Income (Numerator) |  |  | Weighted- Average Shares (Denominator) |  |  | Per Share Amount |
Net income per basic common share |  | $ | 417,415 |  |  |  | 59,496 |  |  | $ | 7.02 |
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities |  |  | — |  |  |  | 160 |  |  |  | (0.02 | )
Net income per diluted common share |  | $ | 417,415 |  |  |  | 59,656 |  |  | $ | 7.00 |

|  | Nine Months Ended September 28, 2024 |
|  | Net Income (Numerator) |  |  | Weighted- Average Shares (Denominator) |  |  | Per Share Amount |
Net income per basic common share |  | $ | 406,436 |  |  |  | 59,314 |  |  | $ | 6.85 |
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities |  |  | — |  |  |  | 157 |  |  |  | (0.02 | )
Net income per diluted common share |  | $ | 406,436 |  |  |  | 59,471 |  |  | $ | 6.83 |

24

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
The Company had 390 thousand and 92 thousand stock options that were antidilutive due to having higher exercise prices than the Company’s average stock price during the three and nine months ended September 27, 2025, respectively. For both the three and nine months ended September 28, 2024, the Company had 130 thousand stock options that were antidilutive. These securities were not included in the computation of diluted EPS. The effect of dilutive securities was calculated using the treasury stock method.
11 Accumulated Other Comprehensive Loss
The components of accumulated other comprehensive loss are detailed as follows (in thousands):

|  | Currency Translation |  |  | Unrealized Loss on Retirement Plans |  |  | Unrealized Loss on Derivative Instruments |  |  | Accumulated Other Comprehensive Loss |
Balance at December 31, 2024 |  | $ | (154,924 | ) |  | $ | (254 | ) |  | $ | (105 | ) |  | $ | (155,283 | )
Other comprehensive income (loss), net of tax |  |  | 45,863 |  |  |  | (106 | ) |  |  | (1,643 | ) |  |  | 44,114 |
Balance at September 27, 2025 |  | $ | (109,061 | ) |  | $ | (360 | ) |  | $ | (1,748 | ) |  | $ | (111,169 | )

12 Business Segment Information
The accounting standards for segment reporting establish standards for reporting information about operating segments in annual financial statements and require selected information for those segments to be presented in interim financial reports of public business enterprises. They also establish standards for related disclosures about products and services, geographic areas and major customers. The Company’s Chief Executive Officer is the chief operating decision maker (“CODM”). The CODM evaluates the business based on our two operating segments: Waters and TA.
The Waters operating segment is primarily in the business of designing, manufacturing, selling and servicing LC and MS instruments, columns and other precision chemistry consumables that can be integrated and used along with other analytical instruments. The TA operating segment is primarily in the business of designing, manufacturing, selling and servicing thermal analysis, rheometry and calorimetry instruments. The Company’s two operating segments have similar economic characteristics; product processes; products and services; types and classes of customers; methods of distribution; and regulatory environments. Because of these similarities, the two segments have been aggregated into one reporting segment for financial statement purposes.
25

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
Net sales for the Company’s products and services are as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Product net sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Waters instrument systems |  | $ | 281,909 |  |  | $ | 265,273 |  |  | $ | 747,099 |  |  | $ | 691,760 |
Chemistry consumables |  |  | 158,480 |  |  |  | 138,935 |  |  |  | 461,102 |  |  |  | 414,227 |
TA instrument systems |  |  | 59,575 |  |  |  | 57,803 |  |  |  | 165,693 |  |  |  | 167,319 |
Total product sales |  |  | 499,964 |  |  |  | 462,011 |  |  |  | 1,373,894 |  |  |  | 1,273,306 |
Service net sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Waters service |  |  | 272,986 |  |  |  | 251,444 |  |  |  | 781,308 |  |  |  | 734,125 |
TA service |  |  | 26,937 |  |  |  | 26,850 |  |  |  | 77,722 |  |  |  | 78,242 |
Total service sales |  |  | 299,923 |  |  |  | 278,294 |  |  |  | 859,030 |  |  |  | 812,367 |
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  | $ | 2,232,924 |  |  | $ | 2,085,673 |

Net sales are attributable to geographic areas based on the region of destination. Geographic sales information is presented below for the three and nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Net Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
China |  | $ | 113,513 |  |  | $ | 100,049 |  |  | $ | 321,516 |  |  | $ | 285,899 |
Asia Other |  |  | 156,201 |  |  |  | 151,280 |  |  |  | 434,914 |  |  |  | 410,420 |
Total Asia |  |  | 269,714 |  |  |  | 251,329 |  |  |  | 756,430 |  |  |  | 696,319 |
Americas: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  |  | 245,255 |  |  |  | 236,182 |  |  |  | 690,645 |  |  |  | 670,952 |
Americas Other |  |  | 47,557 |  |  |  | 42,954 |  |  |  | 138,444 |  |  |  | 123,823 |
Total Americas |  |  | 292,812 |  |  |  | 279,136 |  |  |  | 829,089 |  |  |  | 794,775 |
Europe |  |  | 237,361 |  |  |  | 209,840 |  |  |  | 647,405 |  |  |  | 594,579 |
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  | $ | 2,232,924 |  |  | $ | 2,085,673 |

26

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
Net sales by customer class are as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Pharmaceutical |  | $ | 479,776 |  |  | $ | 430,138 |  |  | $ | 1,332,795 |  |  | $ | 1,220,092 |
Industrial |  |  | 235,669 |  |  |  | 227,740 |  |  |  | 676,689 |  |  |  | 644,459 |
Academic and government |  |  | 84,442 |  |  |  | 82,427 |  |  |  | 223,440 |  |  |  | 221,122 |
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  | $ | 2,232,924 |  |  | $ | 2,085,673 |

2
7

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
Net sales for the Company recognized at a point in time versus over time are as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Net sales recognized at a point in time: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Instrument systems |  | $ | 341,484 |  |  | $ | 323,076 |  |  | $ | 912,792 |  |  | $ | 859,079 |
Chemistry consumables |  |  | 158,480 |  |  |  | 138,935 |  |  |  | 461,102 |  |  |  | 414,227 |
Service sales recognized at a point in time (time & materials) |  |  | 94,927 |  |  |  | 91,045 |  |  |  | 276,315 |  |  |  | 266,445 |
Total net sales recognized at a point in time |  |  | 594,891 |  |  |  | 553,056 |  |  |  | 1,650,209 |  |  |  | 1,539,751 |
Net sales recognized over time: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Service and software maintenance sales recognized over time (contracts) |  |  | 204,996 |  |  |  | 187,249 |  |  |  | 582,715 |  |  |  | 545,922 |
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  | $ | 2,232,924 |  |  | $ | 2,085,673 |

The Company’s segment performance measure is net income attributable to Waters shareholders, which is used by the Company’s CODM when assessing performance and allocating capital and resources to its business. Significant segment expenses are presented in the Company’s consolidated statements of operations. Additional disaggregated significant segment expenses, that are not separately presented on the Company’s consolidated statements of operations, are presented below.
The significant segment expenses, revenues and net income of the Company’s one reportable segment are as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | September 27, 2025 |  |  | September 28, 2024 |
Total sales, net |  | $ | 799,887 |  |  | $ | 740,305 |  |  | $ | 2,232,924 |  |  | $ | 2,085,673 |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Labor costs within selling and administrative and research and development expenses |  |  | (164,157 | ) |  |  | (144,079 | ) |  |  | (480,792 | ) |  |  | (444,340 | )
Material purchases |  |  | (135,157 | ) |  |  | (134,732 | ) |  |  | (350,018 | ) |  |  | (369,132 | )
Labor costs within product and service cost of sales |  |  | (100,275 | ) |  |  | (88,121 | ) |  |  | (284,857 | ) |  |  | (259,843 | )
Other segment expenses |  |  | (208,184 | ) |  |  | (162,241 | ) |  |  | (585,185 | ) |  |  | (478,268 | )
Interest expense and other income, net |  |  | (21,995 | ) |  |  | (17,515 | ) |  |  | (41,375 | ) |  |  | (56,205 | )
Provision for income taxes |  |  | (21,196 | ) |  |  | (32,114 | ) |  |  | (73,282 | ) |  |  | (71,449 | )
Net income |  | $ | 148,923 |  |  | $ | 161,503 |  |  | $ | 417,415 |  |  | $ | 406,436 |

The other segment expenses include depreciation and amortization expenses, facilities and information technology costs, travel, freight, professional fees and all other costs.
2
8

Table of Contents
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) – (Continued)
13 Recent Accounting Standard Changes and Developments
Recently Adopted Accounting Standards
There were no additions to the new accounting pronouncement adoptions as described in the Company’s Annual Report on Form
10-K
for the year ended December 31, 2024. Other amendments to U.S. GAAP that have been issued by the Financial Accounting Standards Board (the “FASB”) or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards
There were no additions to the new accounting pronouncements not yet adopted as described in the Company’s Annual Report on Form
10-K
for the year ended December 31, 2024. Other amendments to U.S. GAAP that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.
29

##### Table of Contents

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

Business Overview

The Company has two operating segments: WatersTM and TATM. Waters products and services primarily consist of high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLCTM” and, together with HPLC, referred to as “LC”), mass spectrometry (“MS”), light scattering and field-flow fractionation instruments (Wyatt), and precision chemistry consumable products and related services. TA products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service sales. The Company’s products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic and government customers. These customers use the Company’s products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals and viscous liquids in various industrial, consumer goods and healthcare products.

Acquisition of BD Biosciences & Diagnostic Solutions Businesses

On July 13, 2025, the Company entered into definitive agreements with BD, Augusta SpinCo Corporation, a Delaware corporation and wholly owned subsidiary of BD (“SpinCo”), and Beta Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Waters (“Merger Sub”), with respect to a Reverse Morris Trust transaction valued at approximately $17.5 billion as of the date of signing, and pursuant to which, subject to the terms and conditions of such definitive agreements, (i) BD will transfer (or cause to be transferred) and SpinCo will accept and assume (or cause to be accepted and assumed) all of the rights, titles and interests to and under certain assets and liabilities relating to BD’s Biosciences and Diagnostic Solutions business, (ii) BD will distribute to its shareholders all of the issued and outstanding shares of common stock, $0.01 par value per share, of SpinCo (“SpinCo Common Stock”) held by BD by way of a pro rata distribution (the “Spin-Off” and the disposition by BD of 100% of the SpinCo Common Stock by way of the Spin-Off, the “Distribution”) and (iii) following the Distribution, Merger Sub will be merged with and into SpinCo, with SpinCo as the surviving entity (the “Merger”), and all SpinCo Common Stock will be converted into the right to receive shares of common stock, $0.01 par value per share, of the Company (“Company Common Stock”), as calculated and subject to adjustment as set forth in the Merger Agreement (as defined herein). When the Merger is completed, SpinCo will become a wholly owned subsidiary of Waters. Upon completion of the Merger, BD’s shareholders are expected to own approximately 39.2% of the combined company, and existing Waters Corporation shareholders are expected to own approximately 60.8% of the combined company. This strategic combination is expected to create a leading global life sciences and diagnostics company with enhanced scale, complementary capabilities and expanded end-market exposure.

The definitive agreements entered into in connection with the transaction include (i) an Agreement and Plan of Merger (the “Merger Agreement”), dated as of July 13, 2025, by and among Waters, BD, SpinCo and Merger Sub, and (ii) a Separation Agreement (the “Separation Agreement”), dated as of July 13, 2025, by and among Waters, BD and SpinCo. As set forth in the Merger Agreement, Waters, BD and SpinCo will also enter into several additional agreements in connection with the transaction.

Prior to, and as a condition of, the Distribution, SpinCo will make a cash payment to BD equal to $4.0 billion (the “SpinCo Cash Distribution”), subject to adjustment for cash, working capital and indebtedness of SpinCo and subject to decrease if additional shares of Company Common Stock will be issued to the Company’s shareholders. The SpinCo Cash Distribution is expected to be paid using proceeds from approximately $4.0 billion of new indebtedness to be incurred by SpinCo prior to the Distribution. The Company is expected to assume all indebtedness incurred by SpinCo in connection with the payment of the SpinCo Cash Distribution upon completion of the Merger. Based on information available through the date of this report, if the transaction closes, the Company estimates it will incur transaction-related expenses and financing fees of approximately $140 million in total.

30

##### Table of Contents

In order to preserve the tax-free nature of the Spin-Off under the Reverse Morris Trust framework, the exchange ratio for the merger consideration specified in the Merger Agreement (the “Exchange Ratio”) may be adjusted and increased, if necessary, on the terms and subject to the conditions set forth in the Merger Agreement. In the event that the Exchange Ratio is adjusted upwards, the Company may issue a pre-closing cash dividend to the shareholders of the Company (the “Waters Special Dividend”) and/or the SpinCo Cash Distribution could be decreased to account for the value of the additional shares issued to the Company’s shareholders.

The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, shareholder approval from the Company’s shareholders and satisfaction of other customary closing conditions.

Acquisition of Halo Labs

On May 20, 2025, the Company completed the acquisition of all of the outstanding equity interests of Optofluidics, Inc., and its wholly owned operating subsidiary, Halo Labs LTD (collectively, “Halo Labs”), for $35 million, net of cash acquired. Halo Labs offers high throughput biopharmaceutical formulation, stability and product quality control tools for aggregate and subvisible particle analysis through the use of custom optics and image processing techniques. As a result of the acquisition, the results of Halo Labs are included in the Company’s consolidated financial statements from the acquisition date.

Tariffs

The Company sells and services its customers in over 35 countries outside of the U.S. and we have manufacturing operations in the U.S., Ireland, U.K. and in Singapore where we utilize subcontractors with worldwide capabilities.

In 2025, the U.S. government issued varying levels of tariffs on all imported goods into the U.S., including a baseline 10% tariff, subject to certain exceptions, which have also prompted retaliatory tariffs by a number of countries, including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries. In addition, a number of new tariffs have been threatened, and the U.S. and other countries continue to negotiate trade arrangements and tariff levels. In August 2025, the U.S. Court of Appeals for the Federal Circuit ruled against certain of the U.S. tariffs that have been implemented. The U.S. government has appealed this ruling, and the U.S. Supreme Court has agreed to hear the case, with oral arguments anticipated in November 2025.

These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company’s consolidated statement of operations and statement of cash flows. In response to currently applicable and potential future tariffs, the Company is continuing to evaluate and implement a series of actions and policies that are intended to offset a portion of the impact of the tariffs on the Company’s financial position and results of operations. While the Company believes that these actions and policies will mitigate a substantial portion of the impact of the tariffs, the Company cannot provide any assurances that the tariffs or any resulting impediments to trade will not have a material effect on the Company’s consolidated statement of operations and statement of cash flows.

In addition to changes in trade policy, the new U.S. administration has implemented a number of other regulatory, policy and personnel changes, including the elimination, downsizing and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants, each of which may be exacerbated by the U.S. government shutdown that began in October 2025. In addition, the administration has changed the composition of and guidance from advisory panels on healthcare practices.

31

##### Table of Contents

Financial Overview

The Company’s operating results are as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (dollars in thousands, except per share data):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |  |  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales |  | $ | 499,964 |  |  | $ | 462,011 |  |  |  | 8 | % |  | $ | 1,373,894 |  |  | $ | 1,273,306 |  |  |  | 8 | %
Service sales |  |  | 299,923 |  |  |  | 278,294 |  |  |  | 8 | % |  |  | 859,030 |  |  |  | 812,367 |  |  |  | 6 | %
Total net sales |  |  | 799,887 |  |  |  | 740,305 |  |  |  | 8 | % |  |  | 2,232,924 |  |  |  | 2,085,673 |  |  |  | 7 | %
Costs and operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of sales |  |  | 327,806 |  |  |  | 301,655 |  |  |  | 9 | % |  |  | 925,958 |  |  |  | 851,685 |  |  |  | 9 | %
Selling and administrative expenses |  |  | 214,229 |  |  |  | 169,097 |  |  |  | 27 | % |  |  | 590,367 |  |  |  | 516,880 |  |  |  | 14 | %
Research and development expenses |  |  | 53,643 |  |  |  | 45,336 |  |  |  | 18 | % |  |  | 148,813 |  |  |  | 136,113 |  |  |  | 9 | %
Purchased intangibles amortization |  |  | 12,095 |  |  |  | 11,759 |  |  |  | 3 | % |  |  | 35,714 |  |  |  | 35,337 |  |  |  | 1 | %
Litigation provision |  |  | — |  |  |  | 1,326 |  |  |  | * | * |  |  | — |  |  |  | 11,568 |  |  |  | * | *
Operating income |  |  | 192,114 |  |  |  | 211,132 |  |  |  | (9 | %) |  |  | 532,072 |  |  |  | 534,090 |  |  |  | — |
Operating income as a % of sales |  |  | 24.0 | % |  |  | 28.5 | % |  |  |  |  |  |  | 23.8 | % |  |  | 25.6 | % |  |  |  |
Other (expense) income, net |  |  | (70 | ) |  |  | (338 | ) |  |  | (79 | %) |  |  | 778 |  |  |  | 1,619 |  |  |  | (52 | %)
Interest expense, net |  |  | (21,925 | ) |  |  | (17,177 | ) |  |  | 28 | % |  |  | (42,153 | ) |  |  | (57,824 | ) |  |  | (27 | %)
Income before income taxes |  |  | 170,119 |  |  |  | 193,617 |  |  |  | (12 | %) |  |  | 490,697 |  |  |  | 477,885 |  |  |  | 3 | %
Provision for income taxes |  |  | 21,196 |  |  |  | 32,114 |  |  |  | (34 | %) |  |  | 73,282 |  |  |  | 71,449 |  |  |  | 3 | %
Net income |  | $ | 148,923 |  |  | $ | 161,503 |  |  |  | (8 | %) |  | $ | 417,415 |  |  | $ | 406,436 |  |  |  | 3 | %
Net income per diluted common share |  | $ | 2.50 |  |  | $ | 2.71 |  |  |  | (8 | %) |  | $ | 7.00 |  |  | $ | 6.83 |  |  |  | 2 | %

** | Percentage not meaningful

The Company’s net sales increased 8% in the third quarter of 2025, as compared to the third quarter of 2024 and 7% for the first nine months of 2025 as compared to the first nine months of 2024. The effect of foreign currency translation had minimal impact on total sales growth for both the third quarter and first nine months of 2025. The net sales growth in the third quarter and first nine months of 2025 was driven by strong customer demand for the Waters Division products and services across most major geographies, end markets and product lines.

Instrument system sales increased 6% for each of the third quarter and first nine months of 2025, respectively, primarily driven by broad-based higher customer demand for our instrument systems in most regions of the world. Foreign currency translation had minimal impact on instrument system sales growth for each of the third quarter of 2025 and first nine months of 2025.

Recurring revenues (combined sales of precision chemistry consumables and services) increased 10% and 8% for the third quarter and first nine months of 2025, respectively, with foreign currency translation increasing sales growth by 1% for the third quarter of 2025 and having a minimal impact on sales growth for the first nine months of 2025. Service revenues increased 8% and 6% for the third quarter and first nine months of 2025, respectively. Chemistry sales growth increased 14% and 11% for the third quarter and first nine months of 2025, respectively. The double-digit chemistry sales growth can be attributed to the uptake in columns and application-specific testing kits to pharmaceutical customers.

Operating income decreased 9% for the third quarter of 2025 primarily due to the impact of the higher sales volume being offset by the change in sales mix, merit increases and approximately $31 million of transaction and integration costs associated with the Merger. In addition, operating income for the third quarter of 2025 included the impact of $6 million of expenses associated with the Company’s new ERP system implementation.

32

##### Table of Contents

Operating income decreased by less than 1% for the first nine months of 2025, due to the impact of the higher sales volume and the absence of severance-related costs associated with a workforce reduction in China and certain litigation settlements incurred in 2024, being partially offset by merit increases and $45 million of transaction and integration costs associated with the Merger. In addition, operating income for the first nine months of 2025 also includes the impact of $14 million of expenses associated with the Company’s new ERP system implementation. The effect of foreign currency translation decreased operating income by $9 million.

In the third quarter and first nine months of 2025, the Company’s interest expense included approximately $14 million of financing costs paid by the Company on behalf of SpinCo in connection with financing activities related to the Merger.

The Company generated $488 million and $522 million of net cash from operating activities in the first nine months of 2025 and 2024, respectively. The first nine months of 2025 included an increase of $24 million more in tax payments associated with the final 2018 Tax Reform Transition payment; $14 million of costs related to the implementation of the Company’s new ERP system; and $14 million of payments made in connection with merger transaction and integration costs. Net cash used in investing activities included capital expenditures related to property, plant, equipment and software capitalization of $74 million and $90 million in the first nine months of 2025 and 2024, respectively, as well as $35 million used for the Halo Labs acquisition in the second quarter of 2025.

On May 22, 2025, the Company and certain of its subsidiaries, as guarantors, entered into an Amendment and Restatement Agreement in respect of that certain Amended and Restated Credit Agreement, dated as of September 17, 2021 and amended as of March 3, 2023, with the lenders and issuing banks party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, pursuant to which the Company, among other things, reduced the aggregate total borrowing capacity of its existing senior unsecured revolving credit facility (the “Credit Facility”) by up to $200 million for an aggregate principal amount of up to $1.8 billion. The Credit Facility will mature on May 22, 2030 subject to the Company’s ability to request, subject to customary conditions, a one-year extension to which each lender may, in its discretion, agree.

In connection with the Merger Agreement to purchase BD’s Biosciences & Diagnostic Solutions business, the Company and a financial institution executed a 364-day bridge facility commitment letter in July of 2025, pursuant to which such financial institution has committed to provide bridge financing of $1.8 billion to fund dividends, fees and expenses related to the transactions contemplated by the Merger Agreement. The bridge facility is expected to be replaced with permanent financing, which may include a delayed draw term loan facility.

33

##### Table of Contents

Results of Operations

Sales by Geography

Geographic sales information is presented below for the three and nine months ended September 27, 2025 and September 28, 2024 (dollars in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |  |  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |
Net Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
China |  | $ | 113,513 |  |  | $ | 100,049 |  |  |  | 13 | % |  | $ | 321,516 |  |  | $ | 285,899 |  |  |  | 12 | %
Asia Other |  |  | 156,201 |  |  |  | 151,280 |  |  |  | 3 | % |  |  | 434,914 |  |  |  | 410,420 |  |  |  | 6 | %
Total Asia |  |  | 269,714 |  |  |  | 251,329 |  |  |  | 7 | % |  |  | 756,430 |  |  |  | 696,319 |  |  |  | 9 | %
Americas: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  |  | 245,255 |  |  |  | 236,182 |  |  |  | 4 | % |  |  | 690,645 |  |  |  | 670,952 |  |  |  | 3 | %
Americas Other |  |  | 47,557 |  |  |  | 42,954 |  |  |  | 11 | % |  |  | 138,444 |  |  |  | 123,823 |  |  |  | 12 | %
Total Americas |  |  | 292,812 |  |  |  | 279,136 |  |  |  | 5 | % |  |  | 829,089 |  |  |  | 794,775 |  |  |  | 4 | %
Europe |  |  | 237,361 |  |  |  | 209,840 |  |  |  | 13 | % |  |  | 647,405 |  |  |  | 594,579 |  |  |  | 9 | %
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  |  | 8 | % |  | $ | 2,232,924 |  |  | $ | 2,085,673 |  |  |  | 7 | %

Geographically, the increase in the Company’s sales in the third quarter and first nine months of 2025 was broad-based across most major regions. Sales growth in China increased 13% and 12% in the third quarter and first nine months of 2025, respectively. In the third quarter and first nine months of 2025, foreign currency translation increased Europe’s sales growth by 8% and 4%, respectively, and decreased Asia’s sales growth by 5%.

Sales by Trade Class

Net sales by customer class are presented below for the three and nine months ended September 27, 2025 and September 28, 2024 (dollars in thousands):

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |  |  | September 27, 2025 |  |  | September 28, 2024 |  |  | % change |
Pharmaceutical |  | $ | 479,776 |  |  | $ | 430,138 |  |  |  | 12 | % |  | $ | 1,332,795 |  |  | $ | 1,220,092 |  |  |  | 9 | %
Industrial |  |  | 235,669 |  |  |  | 227,740 |  |  |  | 3 | % |  |  | 676,689 |  |  |  | 644,459 |  |  |  | 5 | %
Academic and government |  |  | 84,442 |  |  |  | 82,427 |  |  |  | 2 | % |  |  | 223,440 |  |  |  | 221,122 |  |  |  | 1 | %
Total net sales |  | $ | 799,887 |  |  | $ | 740,305 |  |  |  | 8 | % |  | $ | 2,232,924 |  |  | $ | 2,085,673 |  |  |  | 7 | %

During the third quarter of 2025, sales to pharmaceutical customers increased 12%, driven by sales growth in most regions. Foreign currency translation increased pharmaceutical sales growth by 1%. Combined sales to industrial customers, which include material characterization, food, environmental and fine chemical markets, increased 3% in the third quarter of 2025, primarily driven by the broad-based sales growth in most regions except for the U.S., where industrial sales declined by 9% on lower demand for TA instrument systems. Foreign currency translation decreased industrial sales growth by 1%. Combined sales to academic and government customers increased 2% in the third quarter of 2025, with foreign currency translation increasing sales growth by 1%.

34

##### Table of Contents

During the first nine months of 2025, sales to pharmaceutical customers increased 9%, primarily driven by broad-based growth across all regions, with foreign currency translation decreasing pharmaceutical sales growth by 1%. Combined sales to industrial customers increased 5%, with foreign currency having minimal impact on sales growth. Sales to our academic and government customers increased 1% and are highly dependent on when institutions receive funding to purchase our instrument systems and, as such, sales can vary significantly from period to period.

Waters Products and Services Net Sales

Net sales for Waters products and services were as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (dollars in thousands):

|  | Three Months Ended |
|  | September 27, 2025 |  |  | % of Total |  |  | September 28, 2024 |  |  | % of Total |  |  | % change |
Waters instrument systems |  | $ | 281,909 |  |  |  | 40 | % |  | $ | 265,273 |  |  |  | 40 | % |  |  | 6 | %
Chemistry consumables |  |  | 158,480 |  |  |  | 22 | % |  |  | 138,935 |  |  |  | 22 | % |  |  | 14 | %
Total Waters product sales |  |  | 440,389 |  |  |  | 62 | % |  |  | 404,208 |  |  |  | 62 | % |  |  | 9 | %
Waters service |  |  | 272,986 |  |  |  | 38 | % |  |  | 251,444 |  |  |  | 38 | % |  |  | 9 | %
Total Waters net sales |  | $ | 713,375 |  |  |  | 100 | % |  | $ | 655,652 |  |  |  | 100 | % |  |  | 9 | %

|  | Nine Months Ended |
|  | September 27, 2025 |  |  | % of Total |  |  | September 28, 2024 |  |  | % of Total |  |  | % change |
Waters instrument systems |  | $ | 747,099 |  |  |  | 38 | % |  | $ | 691,760 |  |  |  | 38 | % |  |  | 8 | %
Chemistry consumables |  |  | 461,102 |  |  |  | 23 | % |  |  | 414,227 |  |  |  | 22 | % |  |  | 11 | %
Total Waters product sales |  |  | 1,208,201 |  |  |  | 61 | % |  |  | 1,105,987 |  |  |  | 60 | % |  |  | 9 | %
Waters service |  |  | 781,308 |  |  |  | 39 | % |  |  | 734,125 |  |  |  | 40 | % |  |  | 6 | %
Total Waters net sales |  | $ | 1,989,509 |  |  |  | 100 | % |  | $ | 1,840,112 |  |  |  | 100 | % |  |  | 8 | %

Waters products and services sales increased 9% and 8% for the third quarter and first nine months of 2025, respectively, with foreign currency translation having minimal impact on the third quarter of 2025 and decreasing sales growth by 1% for the first nine months of 2025.

Waters instrument system sales increased by 6% and 8% for the third quarter and first nine months of 2025, respectively, due to higher customer demand for our instrument systems led by the increase in sales of LC-MS instrument systems. The effect of foreign currency translation had minimal impact on sales growth for the third quarter and decreased sales growth by 1% for the first nine months of 2025.

Waters chemistry consumables sales grew 14% and 11% for the third quarter and first nine months of 2025, respectively, and was primarily due to the continued demand in most major geographies, driven by the uptake in columns and application-specific testing kits to pharmaceutical customers. Foreign currency translation increased chemistry consumable sales by 1% in the third quarter of 2025 and had minimal impact on the first nine months of 2025.

Waters service sales increased 9% and 6% for the third quarter and first nine months of 2025, respectively, due to higher service demand billing in most major regions, with the effect of foreign currency translation increasing service sales by 1% for the third quarter of 2025 and decreasing service sales by 1% for the first nine months of 2025.

35

##### Table of Contents

TA Product and Services Net Sales

Net sales for TA products and services were as follows for the three and nine months ended September 27, 2025 and September 28, 2024 (dollars in thousands):

|  | Three Months Ended |
|  | September 27, 2025 |  |  | % of Total |  |  | September 28, 2024 |  |  | % of Total |  |  | % change |
TA instrument systems |  | $ | 59,575 |  |  |  | 69 | % |  | $ | 57,803 |  |  |  | 68 | % |  |  | 3 | %
TA service |  |  | 26,937 |  |  |  | 31 | % |  |  | 26,850 |  |  |  | 32 | % |  |  | — |
Total TA net sales |  | $ | 86,512 |  |  |  | 100 | % |  | $ | 84,653 |  |  |  | 100 | % |  |  | 2 | %

|  | Nine Months Ended |
|  | September 27, 2025 |  |  | % of Total |  |  | September 28, 2024 |  |  | % of Total |  |  | % change |
TA instrument systems |  | $ | 165,693 |  |  |  | 68 | % |  | $ | 167,319 |  |  |  | 68 | % |  |  | (1 | %)
TA service |  |  | 77,722 |  |  |  | 32 | % |  |  | 78,242 |  |  |  | 32 | % |  |  | (1 | %)
Total TA net sales |  | $ | 243,415 |  |  |  | 100 | % |  | $ | 245,561 |  |  |  | 100 | % |  |  | (1 | %)

TA sales increased 2% and decreased 1% for the third quarter and first nine months of 2025, respectively, due to lower customer demand for TA instrument systems primarily driven by a 9% and 14% decrease in U.S. sales in the third quarter and first nine months of 2025, respectively. Foreign currency translation increased sales growth by 1% for each of the third quarter and first nine months of 2025, respectively.

Cost of Sales

Cost of sales increased 9% in each of the third quarter and first nine months of 2025. The increase is primarily due to higher sales volume. Cost of sales is affected by many factors, including, but not limited to, foreign currency translation, product mix, product costs of instrument systems and amortization of software platforms.

Selling and Administrative Expenses

Selling and administrative expenses increased 27% and 14% in the third quarter and first nine months of 2025, respectively, primarily due to an increase in merit compensation as well as $27 million and $41 million of transaction and integration costs associated with the Merger in the third quarter and first nine months of 2025, respectively. In addition, 2025 included $6 million and $14 million of expenses associated with the Company’s new ERP system implementation for the third quarter and first nine months of 2025, respectively. The effect of foreign currency translation had minimal impact on selling and administrative expenses for the third quarter and first nine months of 2025.

As a percentage of net sales, selling and administrative expenses were 26.8% and 26.4% for the third quarter and first nine months of 2025, respectively, and 22.8% and 24.8% for the third quarter and first nine months of 2024, respectively.

Research and Development Expenses

Research and development expenses increased 18% and 9% in the third quarter and first nine months of 2025, respectively. The increase in these periods was primarily driven by merit compensation; costs associated with the development of new product and technology initiatives; and $4 million of transaction and integration costs associated with the Merger. The impact of foreign currency exchange decreased expenses by 2% and 1% for the third quarter and first nine months of 2025, respectively.

Litigation Provisions

The Company recorded $12 million of patent litigation settlement provisions and related costs in the first nine months of 2024. No litigation provisions were recorded by the Company in the first nine months of 2025.

36

##### Table of Contents

Interest Expense, net

Interest expense, net increased $5 million and decreased $16 million in the third quarter and first nine months of 2025, respectively. The increase in the third quarter of 2025 is primarily a result of $14 million costs paid by the Company on behalf of SpinCo in connection with financing fees associated with financing activities related to the Merger. The decrease in the first nine months of 2025 is primarily a result of lower average outstanding debt as compared to the third quarter of 2024. The average outstanding debt in these periods was impacted by the timing of the repayment of outstanding debt.

Provision for Income Taxes

The four principal jurisdictions in which the Company manufactures are the U.S., Ireland, the U.K. and Singapore, where the statutory tax rates were 21%, 12.5%, 25% and 17%, respectively, as of September 27, 2025. The Company has a Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% on certain types of income for the period April 1, 2021 through March 31, 2026. The effect of applying the concessionary income tax rate rather than the statutory tax rate to income from qualifying activities in Singapore increased the Company’s net income by $2 million and $9 million and increased the Company’s net income per diluted share by $0.03 and $0.15 for the third quarter of 2025 and 2024, respectively.

The Company’s effective tax rate for the third quarter of 2025 and 2024 was 12.5% and 16.6%, respectively. The decrease in the effective tax rate can be primarily attributed to the impact of discrete tax benefits in the current year and differences in the proportionate amounts of pre-tax income recognized in jurisdictions with different effective tax rates.

The Company’s effective tax rate for the first nine months of 2025 and 2024 was 14.9% and 15.0%, respectively. The decrease in the effective tax rate can be attributed to the impact of differences in the proportionate amounts of pre-tax income recognized in jurisdictions with different effective tax rates.

Effective in 2024, various foreign jurisdictions began implementing aspects of the guidance issued by the Organization for Economic Co-operation and Development related to the new Pillar Two system of global minimum tax rules. These changes in tax law did not have a material impact on the Company’s financial position, results of operations and cash flows for the third quarter and first nine months of 2025. The Company continues to monitor the adoption of the Pillar Two rules in additional jurisdictions.

On July 4, 2025, the U.S. government enacted the One Big Beautiful Tax Bill Act, enacting changes to the United States federal tax code, including adjustments to effective tax rates on certain types of income and certain deduction limitations. The OBBB did not have a material impact on the Company’s financial position, results of operations and cash flows for the three and nine months ended September 27, 2025. The Company will continue to monitor the impact of this Act in future periods.

37

##### Table of Contents

Liquidity and Capital Resources

Condensed Consolidated Statements of Cash Flows (in thousands):

|  | Nine Months Ended |
|  | September 27, 2025 |  |  | September 28, 2024 |
Net income |  | $ | 417,415 |  |  | $ | 406,436 |
Depreciation and amortization |  |  | 153,696 |  |  |  | 143,250 |
Stock-based compensation |  |  | 39,625 |  |  |  | 32,993 |
Deferred income taxes |  |  | (17,274 | ) |  |  | (1,967 | )
Change in accounts receivable |  |  | 26,122 |  |  |  | 27,457 |
Change in inventories |  |  | (65,956 | ) |  |  | (2,032 | )
Change in accounts payable and other current liabilities |  |  | (114,249 | ) |  |  | 36,485 |
Change in deferred revenue and customer advances |  |  | 34,071 |  |  |  | 37,972 |
Other changes |  |  | 14,552 |  |  |  | (158,610 | )
Net cash provided by operating activities |  |  | 488,002 |  |  |  | 521,984 |
Net cash used in investing activities |  |  | (110,120 | ) |  |  | (91,910 | )
Net cash used in financing activities |  |  | (240,541 | ) |  |  | (503,097 | )
Effect of exchange rate changes on cash and cash equivalents |  |  | (3,578 | ) |  |  | 8,461 |
Increase (decrease) in cash and cash equivalents |  | $ | 133,763 |  |  | $ | (64,562 | )

Cash Flow from Operating Activities

Net cash provided by operating activities was $488 million and $522 million during the first nine months of 2025 and 2024, respectively. The decrease in 2025 operating cash flow was primarily a result of higher net income being offset by an increase of $24 million in tax payments associated with the final 2018 Tax Reform Transition payment as compared to the prior year; $34 million of costs related to the implementation of the Company’s new ERP system; and $14 million of payments made in connection with merger transaction and integration costs. The changes within net cash provided by operating activities include the following significant changes in the sources and uses of net cash provided by operating activities, aside from the changes in net income:

| • |  | The changes in accounts receivable were primarily attributable to the timing of payments made by customers and timing of sales. Days sales outstanding was 85 days at September 27, 2025 and 82 days at September 28, 2024.

| • |  | The increase in inventory can primarily be attributed to higher tariffs on material costs as well as an increase in safety stock levels to help navigate tariffs and mitigate any future supply chain issues.

| • |  | Net cash provided from deferred revenue and customer advances results from annual increases in new service contracts as a higher installed base of customers renew annual service contracts.

| • |  | Other changes were attributable to variation in the timing of various provisions, expenditures, prepaid income taxes and accruals in other current assets, other assets and other liabilities.

Cash Flow from Investing Activities

Net cash used in investing activities totaled $110 million and $92 million in the first nine months of 2025 and 2024, respectively. Additions to fixed assets and capitalized software were $74 million and $90 million in the first nine months of 2025 and 2024, respectively.

On May 20, 2025, the Company completed the acquisition of Halo Labs for a total purchase price of $35 million in cash, net of cash acquired. Halo Labs is an innovator of specialized imaging technologies to detect, identify and count interfering materials in therapeutic products, such as cell, protein and gene therapies.

38

##### Table of Contents

Cash Flow from Financing Activities

On May 22, 2025, the Company and certain of its subsidiaries, as guarantors, entered into an Amendment and Restatement Agreement in respect of that certain Amended and Restated Credit Agreement, dated as of September 17, 2021 and amended as of March 3, 2023, with the lenders and issuing banks party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, pursuant to which the Company, among other things, reduced the aggregate total borrowing capacity of its existing senior unsecured revolving credit facility by up to $200 million for an aggregate principal amount of up to $1.8 billion. The Credit Facility will mature on May 22, 2030 subject to the Company’s ability to request, subject to customary conditions, a one-year extension to which each lender may, in its discretion, agree. As of September 27, 2025, the Company had a total of $1.4 billion in outstanding debt, which consisted of $1.3 billion in outstanding senior unsecured notes and $200 million borrowed under its Credit Facility. The Company’s net debt borrowings decreased by $220 million and $530 million during the first nine months of 2025 and 2024, respectively.

Concurrently with the execution of the Merger Agreement, the Company and a financial institution executed a 364-day bridge facility commitment letter, pursuant to which such financial institution has committed to provide bridge financing of $1.8 billion to fund dividends, fees and expenses related to the transactions contemplated by the Merger Agreement, on the terms and conditions set forth therein. The bridge facility is expected to be replaced with permanent financing, which may include a delayed draw term loan facility. The Company incurred $5 million of financing costs that are being amortized over the term of the bridge facility. In addition, in connection with financing activities related to the Merger, the Company paid $14 million of financing costs on behalf of SpinCo. These financing costs were expensed in the three and nine months ended September 27, 2025.

As of September 27, 2025, the Company had entered into interest rate cross-currency swap derivative agreements with durations up to three years with an aggregate notional value of $730 million to hedge the variability in the movement of foreign currency exchange rates on a portion of its euro-denominated and yen-denominated net asset investments. As a result of entering into these agreements, the Company lowered net interest expense by approximately $8 million during both the first nine months of 2025 and 2024. The Company anticipates that these swap agreements will lower net interest expense by approximately $10 million in 2025.

In December 2024, the Company’s Board of Directors authorized the extension of its existing share repurchase program through January 21, 2028. The Company’s remaining authorization is $1.0 billion. The Company did not make any open market share repurchases in 2025 or 2024. The Company repurchased $15 million and $13 million of common stock related to the vesting of restricted stock units during the first nine months of 2025 and 2024, respectively.

The Company received $16 million and $25 million of proceeds from the exercise of stock options and the purchase of shares pursuant to the Company’s employee stock purchase plan during the first nine months of 2025 and 2024, respectively.

The Company had cash, cash equivalents and investments of $459 million as of September 27, 2025. The majority of the Company’s cash and cash equivalents are generated from foreign operations, with $339 million held by foreign subsidiaries as of September 27, 2025, of which $285 million was held in currencies other than U.S. dollars.

Contractual Obligations, Commercial Commitments, Contingent Liabilities and Dividends

A summary of the Company’s contractual obligations and commercial commitments is included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025. The Company reviewed its contractual obligations and commercial commitments as of September 27, 2025 and determined that there were no material changes outside the ordinary course of business from the information set forth in the Annual Report on Form 10-K.

From time to time, the Company and its subsidiaries are involved in various litigation matters arising in the ordinary course of business. The Company believes that it has meritorious arguments in its current litigation matters and that any outcome, either individually or in the aggregate, will not be material to the Company’s financial position or results of operations.

During fiscal year 2025, the Company expects to contribute a total of approximately $3 million to $6 million to its defined benefit plans.

39

##### Table of Contents

The Company has not paid any dividends and has no plans, at this time, to pay any dividends in the future.

In December 2024, the Company’s Board of Directors approved the implementation of a new worldwide ERP system. The Company anticipates spending approximately $130 million on the ERP implementation. The Company expects to use existing cash and its Credit Facility to fund the ERP implementation. For the first nine months of 2025, the Company has incurred $20 million of capitalized costs included in other assets and $14 million of operating costs included in the consolidated statement of operations for the ERP system implementation.

In accordance with the Merger Agreement, prior to, and as a condition of, the Distribution, SpinCo will make a cash payment to BD equal to $4.0 billion, subject to adjustment for cash, working capital and indebtedness of SpinCo and subject to decrease if additional shares of Company Common Stock will be issued to the Company’s shareholders. The SpinCo Cash Distribution is expected to be paid using proceeds from approximately $4.0 billion of new indebtedness to be incurred by SpinCo prior to the Distribution. The Company is expected to assume all indebtedness incurred by SpinCo in connection with the payment of the SpinCo Cash Distribution upon completion of the Merger.

Concurrently with the execution of the Merger Agreement, the Company and certain financial institutions executed a 364-day bridge facility commitment letter, pursuant to which such financial institutions have committed to provide bridge financing of $1.8 billion to fund dividends, fees and expenses related to the transactions contemplated by the Merger Agreement, on the terms and conditions set forth therein. The bridge facility is expected to be replaced with permanent financing, which may include a delayed draw term loan facility. Based on information available through the date of this report, if the Merger closes, the Company estimates it will incur transaction-related expenses and financing fees of approximately $140 million in total.

The Merger Agreement also contains specified termination rights for the Company and BD, including a right allowing the Company or BD to terminate the Merger Agreement if the Merger has not been consummated on or prior to July 13, 2026 (which date may be extended to October 13, 2026 in the event that required regulatory approvals have not been received). Additionally, the Merger Agreement requires the Company to pay BD a termination fee of $733 million if the Merger Agreement is terminated under certain circumstances.

Critical Accounting Policies and Estimates

In the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025, the Company’s most critical accounting policies and estimates upon which its financial status depends were identified as those relating to revenue recognition, valuation of long-lived assets, intangible assets and goodwill, income taxes, uncertain tax positions and business combinations and asset acquisitions. The Company reviewed its policies and determined that those policies remain the Company’s most critical accounting policies for the nine months ended September 27, 2025. The Company did not make any changes in those policies during the nine months ended September 27, 2025.

New Accounting Pronouncements

Please refer to Note 13, Recent Accounting Standard Changes and Developments, in the Condensed Notes to Consolidated Financial Statements.

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, including the information incorporated by reference herein, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements that are not statements of historical fact may be deemed forward-looking statements. You can identify these forward-looking statements by the use of the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “may”, “will”, “would”, “intends”, “suggests”, “appears”, “estimates”, “projects”, “should” and similar expressions, whether in the negative or affirmative. These forward-looking statements are subject to various risks and uncertainties, many of which are outside the control of the Company, including, and without limitation:

| • |  | certain risks related to the Merger, including, without limitation:

| • |  | the risk that one or more closing conditions to the Merger may not be satisfied or waived, on a timely basis or otherwise, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Merger or may require conditions, limitations or restrictions in connection with such approvals or that the required approval by the stockholders of the Company may not be obtained;

40

##### Table of Contents

| • |  | the risk that the Merger may not be completed on the terms or in the time frame expected by the Company, due to such factors as delays in obtaining regulatory approvals due to the U.S. government shutdown that began in October 2025, or at all;

| • |  | the occurrence of any event that could give rise to termination of the Merger;

| • |  | failure to realize the anticipated benefits of the Merger, including as a result of delay in completing the Merger or integrating the businesses of the Company and SpinCo, on the expected timeframe or at all;

| • |  | the ability of the combined company to implement its business strategy and achieve revenue and cost synergies;

| • |  | the risk that stockholder litigation in connection with the Merger or other litigation, settlements or investigations may affect the timing or occurrence of the Merger or result in significant costs of defense, indemnification and liability;

| • |  | the risk that the anticipated tax treatment of the Merger is not obtained;

| • |  | the risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD;

| • |  | risks related to the disruption of management time from ongoing business operations due to the pendency of the Merger, or other effects of the pendency of the Merger on the relationship of the Company with its employees, customers, suppliers, or other counterparties;

| • |  | foreign currency exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar;

| • |  | current global economic, sovereign and political conditions and uncertainties, including the impact of the U.S. government shutdown that began in October 2025; the effect of new or proposed tariff or trade regulations, as well as other new or changed domestic and foreign laws, regulations and policies (or new interpretations thereof); inflation and interest rates; the impacts and costs of war, in particular as a result of the ongoing conflicts between Russia and Ukraine and in the Middle East; and the possibility of further escalation resulting in new geopolitical and regulatory instability;

| • |  | economic conditions in China, trade tensions and tariffs between the U.S. and China and their impact on our business, increased competition from local and international competitors in China, the Chinese government’s ongoing tightening of restrictions on procurement by government-funded customers and other regulatory and other challenges and uncertainties in the Chinese market;

| • |  | the Company’s ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions;

| • |  | changes in timing and demand for the Company’s products among the Company’s customers and various market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain funding;

| • |  | the ability to realize the expected benefits related to the Company’s various cost-saving initiatives, including workforce reductions and organizational restructurings;

| • |  | the introduction of competing products by other companies and loss of market share, as well as pressures on prices from competitors and/or customers;

| • |  | changes in the competitive landscape as a result of changes in ownership, mergers and continued consolidation among the Company’s competitors;

41

##### Table of Contents

| • |  | regulatory, economic and competitive obstacles to new product introductions, lack of acceptance of new products and inability to grow organically through innovation;

| • |  | rapidly changing technology and product obsolescence;

| • |  | the risks related to the development, deployment and use of artificial intelligence (“AI”);

| • |  | a failure to timely and effectively use AI and embed it into new product offerings and services that negatively impacts our competitiveness;

| • |  | risks associated with previous or future acquisitions, strategic investments, joint ventures and divestitures, including risks associated with achieving the anticipated financial results and operational synergies, contingent purchase price payments and expansion of our business into new or developing markets;

| • |  | risks associated with unexpected disruptions in operations, including risks associated with our transition to a new ERP system;

| • |  | risks related to any public health crisis or pandemic, climate change, severe weather and geological conditions or events or other events beyond our control;

| • |  | failure to adequately protect the Company’s intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms;

| • |  | the Company’s ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain;

| • |  | risks associated with third-party sales intermediaries and resellers;

| • |  | the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates, the outcome of ongoing and future tax examinations and changes in legislation affecting the Company’s effective tax rate;

| • |  | the Company’s ability to attract and retain qualified employees and management personnel;

| • |  | risks associated with cybersecurity and our information technology infrastructure, including attempts by third parties, both private and state-sponsored, to defeat the information security measures of the Company or its third-party partners and gain unauthorized access to sensitive and proprietary Company products, services, systems, or data;

| • |  | risks associated with compliance with data privacy and information security laws and regulations regarding the collection, transmission, storage and use of personally identifying information;

| • |  | increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts;

| • |  | regulatory, environmental and logistical obstacles affecting the distribution of the Company’s products, completion of purchase order documentation and the ability of customers to obtain letters of credit or other financing alternatives;

| • |  | risks associated with litigation and other legal and regulatory proceedings; and

| • |  | the impact and costs incurred from changes in accounting principles and practices.

Certain of these and other factors are discussed under the heading “Risk Factors” under Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements, whether because of these factors or for other reasons. All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in this report. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

42

##### Table of Contents

Item 3: Quantitative and Qualitative Disclosures About Market Risk

The Company is also exposed to the risk of exchange rate fluctuations. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of September 27, 2025 and December 31, 2024, $339 million out of $459 million and $275 million out of $325 million, respectively, of the Company’s total cash and cash equivalents were held by foreign subsidiaries. In addition, $285 million out of $459 million and $226 million out of $325 million of cash and cash equivalents were held in currencies other than the U.S. dollar at September 27, 2025 and December 31, 2024, respectively. As of September 27, 2025, the Company had no holdings in auction rate securities or commercial paper issued by structured investment vehicles.

Assuming a hypothetical adverse change of 10% in year-end exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash and cash equivalents held in currencies other than the U.S. dollar as of September 27, 2025 would decrease by approximately $29 million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ equity.

Assuming a hypothetical adverse change of 10% in year-end exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of September 27, 2025 would increase pre-tax earnings by approximately $2 million. Assuming a hypothetical adverse change of 10% in year-end exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of September 27, 2025 would increase by approximately $78 million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ equity. The related impact on interest income would not have a material effect on pre-tax earnings.

There have been no other material changes in the Company’s market risk during the nine months ended September 27, 2025. For information regarding the Company’s market risk, refer to Item 7A of Part II of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025.

Item 4: Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s chief executive officer and chief financial officer (principal executive officer and principal financial officer), with the participation of management, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of September 27, 2025 (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control Over Financial Reporting

No change was identified in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 27, 2025 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

43

##### Table of Contents

Part II:
Other Information
Item 1: Legal Proceedings
There have been no material changes in the Company’s legal proceedings during the nine months ended September 27, 2025 as described in Item 3 of Part I of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025.
Item 1A:
Risk Factors
Information regarding risk factors of the Company is set forth under the heading “Risk Factors” under Part I, Item 1A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 25, 2025. The Company reviewed its risk factors as of September 27, 2025 and determined that, except as set forth below, there were no material changes from the ones set forth in the Annual Report on Form 10-K. Furthermore, note the discussion of certain factors under the subheading “Special Note Regarding Forward-Looking Statements” in Part I, Item 2 of this Quarterly Report on Form 10-Q. These risks are not the only ones facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial may have a material adverse effect on the Company’s business, financial condition and operating results.
RISKS RELATED TO THE MERGER
The consummation of the Merger is subject to significant risks and uncertainties and may not be consummated on the expected terms, if at all. Further, our failure to successfully integrate BD’s Biosciences and Diagnostic Solutions business within the expected timeline could adversely affect the combined company’s future results.
On July 13, 2025, the Company entered into the Merger Agreement and the Separation Agreement to purchase and combine BD’s Biosciences & Diagnostic Solutions business with the Company. The transaction is structured as a Reverse Morris Trust transaction, where BD’s Biosciences & Diagnostic Solutions business will be spun off to BD shareholders (such spin-off, the “Spin-Off”) and simultaneously merged with a wholly owned subsidiary of the Company. Consummation of the Merger is subject to receipt of required regulatory approvals, approval from the Company’s shareholders, the receipt of a private letter ruling from the Internal Revenue Service (the “IRS”) and satisfaction of other customary closing conditions. As a result, there can be no assurance that the Merger will be consummated on the expected terms, in accordance with the Company’s anticipated timeline, or at all. Any delay in consummation of the Merger, such as delays in obtaining regulatory approvals due to the U.S. government shutdown that began in October 2025, could result in increased transaction costs and professional fees and could cause disruptions to the Company’s business or business relationships, which could have an adverse impact on the Company’s results of operations. Additionally, if the Merger Agreement is terminated under certain circumstances prior to the consummation of the Merger, the Company will be required to pay BD a termination fee of $733 million.
In order to preserve the tax-free nature of the Spin-Off, the exchange ratio for the Merger (the “Exchange Ratio”) may be adjusted and increased if necessary, on the terms and subject to the conditions set forth in the Merger Agreement. In the event that the Exchange Ratio is adjusted upwards, the Company may issue a special dividend to the shareholders of the Company (the “Waters Special Dividend”) and/or the cash distribution to be paid to BD’s shareholders (the “SpinCo Cash Distribution”) may be decreased to account for the value of the additional shares issued to the Company’s shareholders. In addition, the grant of the IRS ruling is within the discretion of the IRS. We can offer no assurance concerning the extent of our and BD’s overlapping shareholdings at any closing of the Merger or assurance that the IRS ruling will be received. As a result, we can offer no assurance regarding the number of shares of common stock of the Company (the “Company Common Stock”) that may be issued in connection with the Merger. Any issuance of shares of Company Common Stock to shareholders of BD will dilute the ownership and voting interests of the Company’s existing shareholders. In addition, the Company’s stock price has been volatile since the announcement of the Merger, and it may continue to fluctuate significantly in response to the pendency of the Merger and any developments related thereto.
44

Table of Contents
If consummated, the success of the Merger will depend, in significant part, on the successful integration of BD’s Biosciences and Diagnostic Solutions business with the business of the Company and our ability to grow the revenue of the combined company and realize the anticipated strategic benefits and synergies from the Merger. Difficulties in integrating the practices and operations of these two businesses may result in the combined company performing differently than expected, operational challenges or the delay or failure to realize anticipated benefits and synergies and could have an adverse effect on the Company’s business, financial condition, results of operations and/or cash flows.
The amount of debt that the Company may incur and/or assume in connection with the Merger is uncertain and may be substantial.
The SpinCo Cash Distribution is expected to be paid using proceeds from approximately $4.0 billion of new indebtedness to be incurred by SpinCo prior to the Distribution. The Company is expected to assume all indebtedness incurred by SpinCo in connection with the payment of the SpinCo Cash Distribution upon completion of the Merger. Additionally, as part of the Merger, the Company may be required to pay the Waters Special Dividend to the Company’s shareholders in an amount ranging from zero to approximately $1.8 billion, depending on the number of shares of Company Common Stock that may be issued in connection with the Merger. If the Waters Special Dividend is paid, the Company expects to fund it with new indebtedness and has entered into a 364-day bridge facility commitment letter with a financial institution in this regard, which is described in more detail under “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Cash Flow from Financing Activities.” The size of the Waters Special Dividend that will ultimately be declared is uncertain and will remain so until the closing of the Merger. The Company’s substantially increased indebtedness following the consummation of the Merger may have the effect of, among other things, reducing the Company’s flexibility to respond to changing business and economic conditions, lowering its credit ratings, increasing its borrowing costs and/or requiring the Company to reduce or delay investments, strategic acquisitions and capital expenditures or seek additional capital to refinance its indebtedness.
Item 2:
Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer
In January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This program replaced the remaining amounts available under the pre-existing authorization. In December 2020, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2023. In December 2022, the Company’s Board of Directors amended and extended this repurchase program’s term by one year such that it expired on January 21, 2024 and increased the total authorization level to $4.8 billion, an increase of $750 million. In December 2023, the Company’s Board of Directors authorized the extension of the share repurchase program through January 21, 2025. In December 2024, the Company’s Board of Directors authorized the extension of the existing share repurchase program through January 21, 2028. As of September 27, 2025, the Company had repurchased an aggregate of 15.2 million shares at a cost of $3.8 billion under the January 2019 repurchase program and had a total of $1.0 billion authorized for future repurchases. The size and timing of these purchases, if any, will depend on our stock price and market and business conditions, as well as other factors.
45

Table of Contents
The following table summarizes the Company’s stock repurchase activity for the three months ended September 27, 2025:

Period |  | Total Number of Shares Purchased (1) |  |  | Average Price Paid per Share |  |  | Total Number of Shares Purchased as Part of Publicly Announced Programs |  |  | Maximum Dollar Value of Shares That May Yet Be Purchased Under the Programs (in thousands) |
June 29, 2025 to July 26, 2025 |  |  | 200 |  |  | $ | 297.32 |  |  |  | — |  |  | $ | 961,207 |
July 27, 2025 to August 23, 2025 |  |  | 58 |  |  | $ | 289.40 |  |  |  | — |  |  | $ | 961,207 |
August 24, 2025 to September 27, 2025 |  |  | 464 |  |  | $ | 296.25 |  |  |  | — |  |  | $ | 961,207 |
Total |  |  | 722 |  |  | $ | 296.00 |  |  |  | — |  |  | $ | 961,207 |

(1) | All shares repurchased as referenced in the table above related to the vesting of restricted stock during the three months ended September 27, 2025.

Item 5:
Other Information
Insider Trading Arrangements and Related Disclosures
During the nine months ended September 27, 2025, none
of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
4
6

##### Table of Contents

Item 6: Exhibits

Exhibit Number |  | Description of Document
2.1 |  | Separation Agreement, dated as of July 13, 2025, by and among Waters Corporation, Becton, Dickinson and Company and Augusta SpinCo Corporation (incorporated by reference to the Registrant’s Report on Form 8-K dated July 14, 2025 (File No. 001-14010)). †
2.2 |  | Agreement and Plan of Merger, dated as of July 13, 2025, by and among Waters Corporation, Becton, Dickinson and Company, Beta Merger Sub, Inc. and Augusta SpinCo Corporation (incorporated by reference to the Registrant’s Report on Form 8-K dated July 14, 2025 (File No. 001-14010)). †
31.1 |  | Chief Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 |  | Chief Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 |  | Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
32.2 |  | Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *
101 |  | The following materials from Waters Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 27, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets (unaudited), (ii) the Consolidated Statements of Operations (unaudited), (iii) the Consolidated Statements of Comprehensive Income (unaudited), (iv) the Consolidated Statements of Cash Flows (unaudited), (v) the Consolidated Statements of Stockholders’ Equity (unaudited) and (vi) Condensed Notes to Consolidated Financial Statements (unaudited).
104 |  | Cover Page Interactive Date File (formatted in iXBRL and contained in Exhibit 101).

† | Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.

* | This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.

47

##### Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WATERS CORPORATION
/s/ Amol Chaubal
Amol Chaubal
Senior Vice President and Chief Financial Officer
(Principal Financial Officer)
(Principal Accounting Officer)

Date: November 4, 2025

48